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Abstract 
Congenital heart disease (CHD) is the most common birth defect in infants. 
Identifying factors that are critical to embryonic heart development or CHDs in general 
could further our understanding of the disease and may lead to new strategies of its 
prevention and treatment. Endothelial nitric oxide synthase (NOS3/eNOS) is known for 
many important biological functions including vasodilation, vascular homeostasis and 
angiogenesis. Previous studies have shown that deficiency in NOS3 results in congenital 
septal defects, cardiac hypertrophy and postnatal heart failure. In addition, NOS3 is 
pivotal to morphogenesis of aortic valve and myocardial capillary development. The aim 
of my thesis was to investigate the role of NOS3 in the embryonic and adult heart. I 
discovered that NOS3 deficiency resulted in coronary artery hypoplasia in fetal mice and 
spontaneous myocardial infarction in postnatal hearts. Coronary artery diameters, vessel 
density and volume were significantly decreased in NOS3-/- mice at postnatal day 0. Lack 
of NOS3 also down-regulated the expression of Gata4, Wilms tumor-1, vascular 
endothelial growth factor, basic fibroblast growth factor and erythropoietin in the 
embryonic heart at E12.5, and inhibited migration of epicardial cells into the myocardium. 
In addition, my data show that the overall size and length of mitral and tricuspid valves 
were decreased in NOS3-/- compared with WT mice. Echocardiographic assessment 
showed significant regurgitation of mitral and tricuspid valves during systole in NOS3-/- 
mice. Immunostaining of Snail1 was performed in the embryonic heart. Snail1 positive 
and total mesenchymal cells in the AV cushion were decreased in NOS3-/- compared with 
WT mice at E10.5 and E12.5. Finally, in the adult aortic valves, NOS3 is important in 
inhibition of thrombosis formation. Deficiency in NOS3 leads to aortic valve thrombosis 
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and calcification. At 12 months old, 72% (13/18) of NOS3-/- mice showed severe 
spontaneous aortic valve thrombosis compared with WT mice (0/12). Ex vivo culture of 
aortic valves showed that platelet aggregation and adhesion were significantly increased 
in NOS3-/- aortic valves compared with WT aortic valves. There was also a significant 
regurgitation of the aortic valve during systole in the NOS3
-/-
 compared with WT mice. In 
addition, NOS3 deficiency resulted in significant aortic valve stenosis, calcification and 
fibrosis. In summary, these data suggest NOS3 plays a critical role in embryonic heart 
development and morphogenesis of coronary arteries and inhibits thrombosis formation 
in the adult aortic valves.  
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1 CHAPTER 1 
Literature Review 
1.1 Congenital Heart Disease 
Congenital heart disease refers to a defect in the structure of the heart and/or 
vessels present at birth. This defect, however, can be detected earlier by prenatal 
diagnosis such as fetal echocardiography. The disease affects up to 5% of people of the 
general population and is the leading cause of death in infants during the first year of life in 
the industrialized countries.1, 2 It is estimated that 96,000 adults in Canada have congenital 
heart disease.3 These patients have increased risk of arrhythmia, bacterial endocarditis and 
heart failure later in life.4 Thus, congenital heart disease is a major cause of mortality and 
morbidity in both infants and adults. The cause of congenital heart disease may be either 
genetic or environmental, but is usually a combination of both. It is estimated that only 15% 
of all congenital heart disease can be traced to a known cause.4 Some genetic factors have 
been linked to cause congenital heart disease, while the majority of factors are still unknown. 
Thus understanding the mechanisms that regulate the formation of the heart and the 
coronary artery system could further our understanding of the disease and lead to new 
strategies of its prevention or treatment. 
1.2 Valvular Heart Disease 
Valvular heart disease is a significant health problem and contributes to more than 
44,000 deaths in United States annually.5 The causes of valvular heart disease include 
congenital malformations such as bicuspid aortic valves and rheumatic disease which is 
secondary to bacterial infection. Congenital valve disease affects about 2% of the general 
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population.6, 7 More specifically, bicuspid aortic valve disease is the most common 
congenital heart defect.8-10 As the name suggests, the bicuspid aortic valve is typically 
made of 2 unequal-sized leaflets rather than the normal three. Bicuspid aortic valve 
disease is often asymptomatic during childhood. In adulthood, complications commonly 
arise and the burden of disease from bicuspid aortic valve disease is more significant than 
any other congenital heart disease. Despite this heavy economic burden, our 
understanding of bicuspid aortic valve disease is limited. Incidence of valvular heart 
disease dramatically increases to more than 13.3% over the age of 75.11, 12 The disease 
may manifest as valvular stenosis, an obstruction of outflow, or as regurgitation, a 
defective closure resulting in backward flow. Congenital valve malformations tend to 
cluster in families among both close and distant relatives, suggesting a genetic 
component to this disease.13, 14 However, underlying molecular mechanisms responsible 
for congenital valve disease are still not fully understood.  
1.3 Hypoplastic Coronary Artery Disease 
Congenital coronary anomalies affect up to 5% of the general population.15, 16 Most 
of them are asymptomatic and therefore often unrecognized. However, people with major 
congenital coronary artery malformation are at greater risk for myocardial ischemia, 
infarction and sudden cardiac death.17 Hypoplastic coronary artery disease (HCAD) is a rare 
congenital coronary abnormality. It is characterized by malformation of one or more major 
branches of the coronary arteries with a marked decrease in luminal diameter and length.18-20 
HCAD can be asymptomatic, but it can be associated with myocardial infarction and sudden 
cardiac death under stress, usually in the form of intense physical activity.17, 21 However, the 
molecular mechanisms responsible for development of HCAD remain unclear.  
3 
 
1.4 Formation of the Four-Chambered Heart 
Heart development is a complex process involving many coordinated processes 
including, migration, differentiation and proliferation of cardiac progenitors. The cardiac 
progenitors are derived from three distinct origins: the anterior lateral plate mesoderm or the 
primary heart field; the second heart field which is located dorsal and anterior to the primary 
heart field; and the cardiac neural crest from the dorsal neural tube.22-24 In addition, the 
epicardium is also a source of cardiac progenitors which give rise to coronary arteries and 
possibly cardiomyocytes.24, 25 Cardiac morphogenesis starts from the fusion of the 2 patches 
of anterior lateral plate mesoderm to form the cardiac crescent at embryonic day (E) 7.5 in 
the mouse embryo.26 By E8 the primitive heart (or heart tube) is formed. As the heart tube 
forms, cells from the second heart field migrate into the dorsal aspect to the heart tube in the 
pharyngeal mesoderm. Upon rightward looping of the heart tube, they cross the pharyngeal 
mesoderm and populate the outflow tract with contributions also from the cardiac neural 
crest. As the heart develops, the primitive heart undergoes specification processes including 
chamber specification, septation and trabeculation. The atrial and ventricular septum starts 
to form at E10. Multiple primordia contribute to a central mesenchymal mass, including the 
mesenchyme on the leading edge of the primary atrial septum, the atrioventricular 
endocardial cushions, and the cap of mesenchyme on the spina vestibule.27, 28 Fusion of 
these components closes the ostium primum, completing atrial and atrioventricular septation. 
The mitral and tricuspid valves are derived from the endocardial cushion while the aortic 
and pulmonary valves are formed from endocardial cushions and with a contribution of 
neural crest cells.29 The formation of atrioventricular septum and valves is tightly regulated 
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by coordinated cell proliferation, apoptosis and remodelling. By E14.5, a fully functional 
four-chambered heart is formed in mice.26 
1.5 Formation of the Coronary Arteries 
The development of the coronary vessels is an important event at the later stages of 
cardiogenesis. Coronary development starts at E9.5 in mice from proepicardial organ (PEO) 
located at the pericardial surface of the septum transversum close to the sinus venosus.30, 31 
Cells from PEO migrate and spread over the surface of the myocardium to become the 
epicardium. Concurrent with formation of the epithelium, some epithelial cells migrate 
further into the subepicardial space and undergo epithelial-mesenchymal transition (EMT) 
to become mesenchymal cells, which migrate throughout the developing myocardium and 
give rise to vascular smooth muscle cells, fibroblasts and possibly endothelial cells, and 
form coronary vasculature of the heart. The proximal ends of the coronary arteries connect 
to the ascending aorta through coronary orifices at the level of the left and right sinuses of 
the semilunar valves. Coronary veins connect to the right atrium via the coronary sinus. By 
E15.5, a complete coronary vascular system is established.30, 31 Over the past decade, many 
factors have been shown to be crucial in the formation of the coronary arteries,30, 32 but the 
role of NOS3 in this process is still not well understood.  
1.6 Atrioventricular Valve Development 
The atrioventricular (AV) valve development starts at E9 with the formation of 
endocardial cushions. A subpopulation of endocardial cells of the endocardial cushion 
undergoes endothelial-to-mesenchymal transition (EndMT) and provides the primary cell 
source for the development of AV valves.33 Proliferation of the mesenchymal cells and 
matrix deposition extend the cushions into the cardiac lumen and form primordia of each 
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distinct valve. This is followed by elongation and remodeling of the valve primordia, 
which leads to the gradual maturation of valves by E15.34 EndMT is a crucial process for 
proper formation of AV valves.35 Transforming growth factor (Tgfβ), bone 
morphogenetic protein (Bmp)-2, and Snail1 have been shown to promote EndMT and 
valve formation.36  In addition, Notch-dependent NOS3 activation has been shown to 
promote EndMT in the developing atrioventricular (AV) canal from E9 to E11.5 via 
activation of the PI3-kinase/Akt pathway.37 
1.7 Factors in Heart Development 
The formation of the heart is highly regulated and complex in nature. Studies have 
shown both environmental and genetic factors play a crucial role in heart development.38 
Well known environmental factors such as drug abuse, alcohol abuse and maternal 
diabetes all have been linked to as risk factors for congenital heart disease.39 In addition, 
several lines of evidence also support a genetic contribution to congenital heart disease.40, 
41 Over the past 50 years, through the use of genetically modified animals various factors 
have been identified to govern different aspects of heart development. In 2003, the 
completion of the human genome project allowed us to further test the importance of 
these factors in humans through the use of gene sequencing. These factors can be 
grouped into 2 categories: first, transcription factors that are responsible for initiating and 
regulating heart development and second, growth factors that acts as effectors to guide 
heart development.  
1.7.1 Transcription Factors in Heart Development 
Gata4 has been shown to be crucial in both human and murine heart 
development.42, 43 Interestingly, Gata4 is one of the earliest transcription factors 
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expressed in the developing heart.44  More specifically, Gata4 mRNA can be detected as 
early as E7.0 in the pre-cardiac mesoderm and during formation and bending of the heart 
tube in endocardium, myocardium and pre-cardiac mesoderm at E8.0.44 It is worth noting 
that abundant Gata4 continues to be expressed in the heart throughout adulthood. 
Transgenic mice with inactivation of the Gata4 gene die during embryonic development 
due to the failure of ventral morphogenesis and heart tube formation between E8.0-
E9.0.45, 46 In addition, functional mutation of GATA4 in humans has been linked to 
congenital heart disease.47 Together, as a master regulator of cardiogenesis, Gata4 is 
required during embryonic heart development in both mice and humans.  
Nkx2.5, a direct binding partner of Gata4 through its homeodomain, has also been 
shown to be involved in early heart development.48, 49 As one of the earliest identified 
factors associated with human congenital heart disease, Nkx2.5 has been studied quite 
extensively throughout different organisms.50-53 Mutations have been identified in 
patients with a variety of congenital heart malformations including septal defects, 
conotruncal abnormalities, and atrioventricular conduction defects. Similar to Gata4, 
Nkx2.5 is also expressed early during heart development.54 Nkx2.5 is thought to act 
together with Gata4 to control the complex and precise regulation of heart development.  
Heart development involves the precise looping and formation of the heart 
chambers, the development of the cardiac conduction system as well as the coronary 
vascular system. Wilm’s tumor -1 (Wt1) is a transcription factor that is involved in the 
formation of the coronary vasculature system. Wt1 has been shown to regulates 
epicardial epithelial to mesenchymal transition (EMT), a process which is required for 
coronary artery formation.55, 56 Wt1 regulates epicardial EMT and heart development 
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through multiple signaling pathways. It has been shown Wt1 promotes canonical Wnt/β-
catenin signaling and Raldh2, a regulator of retinoic acid signaling.55, 56 By controlling 
epicardial EMT, Wt1 directs the coronary vasculature development in the heart. 
 Snail1, a zinc finger transcriptional repressor, has been studied extensively in 
developmental EMT. Mice with conditional knockout of Snail1 form a mesodermal layer 
with distinctly epithelial characteristics and die early in gastrulation around E7.5.57 Snail1 
is also required for EMT-mediated mesoderm formation in zebrafish and for neural crest 
cell migration in mice.58 EMT is a crucial process during heart development which 
contributes to coronary artery formation, valve formation and septation of the ventricles 
and atria.59, 60 Taken together, the role of Snail1 in EMT and the importance of EMT in 
heart development, Snail1 dictates the proper formation of the heart by regulating EMT. 
 The transcription factors listed above are factors investigated in the current thesis, 
but this only represents the tip of the iceberg, as the majority of the transcription factors 
that are important during various aspects of heart development are beyond the scope of 
this thesis. Other transcription factors that are notable include Tbx5, Mef2C, NFATc1 
and Pitx2. Txb5 is a T-box containing transcription factor, that is expressed early in heart 
development at E8.0.61 TBX5 deficiency in humans results in Holt-Oram syndrome, a 
condition inherited as autosomal dominant , and the range of cardiac abnormalities 
include atrioventricular blocks, failure of septa formation and hypoplastic left heart 
syndrome, aortic stenosis, mitral valve prolapse, and the tetralogy of Fallot.62 Mef2C is a 
member of the myocyte-specific enhancer factor 2 (Mef2) family of transcription factors 
and is also important for cardiac muscle formation.63 In addition, recent discoveries 
reveal the specific role of Mef2C in second heart field development. Mef2C drives the 
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development of the right ventricle, septum formation and contributes to the proper 
development of the atria, the outflow tract, pulmonary and aortic valves and endothelial 
cells in the coronary artery.64 Specific deletion of Mef2C in the heart results in right 
ventricle defects as well failure of the heart tube to undergo looping morphogenesis.65  
NFATc1, a transcription factor required for heart valve formation in mice, starts to be 
expressed early during murine heart development around E8.5.66, 67  Specific deletion of 
NFATc1 in the hearts results in complete absence of pulmonary and aortic valves, leading 
to congestive heart failure and death of the animal between E13.5-E17.5.67 Finally, Pitx2 
is a crucial transcription factor in early heart development as it is responsible for the 
establishment of left-right symmetry.68 PITX2 mutations in humans result in varies 
complex syndromes such as Axenfeld-Rieger syndrome (ARS), iridogoniodysgenesis 
syndrome (IGDS), and sporadic cases of anterior segment mesenchymal dysgenesis.69-71  
1.7.2 Growth Factors in Heart Development 
Growth factor signalling is a crucial component in heart development. It provides 
the local niche for the migration and expansion of cardiomyocytes and other precursors in 
the heart. Many growth factors have been identified, via mainly genetically modified 
animals, to provide fundamental insights into their role in heart development. More 
specifically, growth factors in the heart can acts as a chemokine that attracts precursors in 
the epicardium to migrate into the myocardium and form coronary vasculature32 Without 
the proper guidance provided by the local growth factors, coronary vasculature cannot be 
correctly formed. 
Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) 
have been shown to the crucial in coronary artery formation. More specifically, inhibition 
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of VEGF and FGF decreases capillary formation and arterial growth.30, 32, 72 During early 
stages of coronary artery development, the expression FGF is high throughout the 
myocardium and VEGF expression is locally high at the site of early vascular tube 
formation.73, 74 It is worth noting that both factors have the potential to stimulate vascular 
growth in the embryonic heart.75 Myocardium specific overexpression of Fgf increases 
coronary artery density and branching, while Vegf conditional knockout impairs the 
recovery of coronary vessels from ischemic injury in mice.76, 77  Interestingly, the arterial 
diameter can be increased via the administration of anti-FGF-2 and anti-VEGF 
antibodies.78 These data suggest VEGF and FGF are crucial growth factors that is 
required during coronary artery formation.  
Erythropoietin (EPO) is known for its vital role in the formation of red blood cells 
by binding to its receptor (EPOR).79 Through the use of genetically modified animal, Epo 
signalling through its receptor Epor was shown to be crucial in embryonic coronary 
artery formation. Epor is expressed in the epicardium and pericardium of the developing 
heart from E10 to E14. In Epor knockout mouse embryos, the epicardium was thin and 
detached from the myocardium. In addition, the coronary vessel network was severely 
affected with disorganized structures.79 This shows that inactivation of the Epo pathway 
leads to decreased epicardial precursors, and the detachment of the epicardium from the 
myocardium inhibited the crucial EMT process that is required for coronary artery 
formation.  
1.8 Endothelial Activation and Thrombosis Formation 
Endothelial activation generally refers to endothelial dysfunction or damage 
which may eventually contribute to vascular disease or thrombosis formation. Endothelial 
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activation represents a change in phenotype of the endothelial cells from the quiescent 
state towards a state that involves host defense response.80, 81 Most cardiovascular risk 
factors activate the endothelium which results in expression of chemokines, cytokines, 
and adhesion molecules that interact with the immune system to target inflammation to 
damaged tissues.80, 81 The molecular change involved in endothelial activation is 
switching from NO-mediated cellular processes, such as cGMP signalling or s-
nitrosylation, to the activation of ROS signalling.82 This process is largely mediated by 
the uncoupling of NOS.83 Uncoupling of NOS3 is related to the depletion of important 
cofactor BH4, phosphorylation of specific residues of NOS3, mainly on residues  serine 
114, threonine 495, serine 615, serine 633 and serine 1177, increased S-glutathionylation 
and increased production of peroxynitrite.83, 84  NOS3 ROS production deteriorates 
cellular function via phosphorylation of transcription factors, induces adhesion molecule 
production and protease activation. Endothelial activation and ROS production can be a 
part of the normal host defense. It is when this process is extended, prolonged and/or in 
combination of the pro-inflammatory stimuli that results in endothelial damage.85 The 
damaged endothelium then contributes to vascular disease such as atherosclerosis or 
thrombosis formation.  
Endothelium integrity not only depends on the extent of injury, but also on the 
ability of the endogenous capacity to repair.86 Repair mechanisms mainly occur in two 
ways. First is the replication of the mature endothelial cells which replaces the lost and 
damaged cells. Second is recruitment of circulating progenitor cells. These cells originate 
from the bone marrow and upon injury can be recruited to the site of injury to 
differentiate into endothelial cells.87, 88 Mobilization of these cells is in part NO-
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dependent. Factors that have been shown to improve endothelial function and NO 
bioavailability such as statins and exercise have also been shown to promote endothelial 
progenitor cell mobilization.89-91 Therefore, it is a balance of repair and extent of 
endothelial damage that ultimately determines the integrity of the endothelium. 
Endothelial activation and damage, if unresolved, may result in thrombosis formation and 
vascular disease.  
Arterial and venous thrombosis and thrombus embolization can be life threatening 
and if left untreated may lead to death. Arterial and venous thrombosis are blood clots 
that are formed in arteries and veins. The arterial clot is predominantly caused by 
platelets aggregation while a venous thrombus is mainly composed of fibrin and red 
blood cells and variable amount of platelets and white cells.92-94 Thrombi can occlude 
vessels locally at the site of formation or travel to other organs through blood and cause 
occlusion in distal vessels. Occlusions in the brain or the heart are especially dangerous 
and can cause stroke or heart attacks. However, thrombi may be spontaneously formed 
and  lysed by local conversion of plasminogen to plasmin, a proteolytic enzyme which 
degrades plasma fibrinogen.95 The dynamics of platelet deposition and thrombus 
formation are modulated by the type of injury and the local geometry at the site of 
damage.92-94 Arterial thrombosis formation involves 3 distinct steps. First, platelets 
adhere at the recognition sites and are activated by the thromboactive substrates. The 
second step involves platelets spreading on the surface of attachment. Finally, platelets 
aggregate with each other to form a platelet plug. This process greatly depends on the 
efficiency of platelet recruitment and local geometry. Once platelets aggregate, other 
blood cells are recruited such as red blood cells, neutrophils and sometimes monocytes.92-
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94 The formation of a thrombus on the heart valve usually involves prosthetic valves. The 
process of thrombus formation is initiated during heart valve replacement surgery. The 
damaged peri-valvular tissue and prosthetic materials activate platelets as soon as blood 
starts flowing across the prosthetic valve. This results in the immediate deposition of 
platelets. In addition, the abnormal hemodynamic characteristics of mechanical prosthetic 
devices promote platelet activation.96-99 It is worth noting that bioprosthetic valves made 
from animals such as pig are considerably less thrombogenic mainly because of the 
biological properties of materials used in their construction.96-99 The spontaneous 
formation of a thrombus on the aortic valve is extremely rare in humans with only less 
than a dozen of case reports in the literature.100-109 However, aortic valve thrombosis is 
extremely dangerous, as it could lead to embolization, and subsequent cerebrovascular 
events such as stroke, myocardial infarction and death.101-104, 108 Surgery is the only 
available treatment for these patients. Anti-coagulant therapy is still under debate as to 
whether the beneficial effects outweigh the deleterious effects.100 To our knowledge, 
spontaneous aortic valve thrombosis has never been studied in animal models. 
1.9 Aortic Valve Calcification 
Calcific aortic valve stenosis (CAVS) is the most common valvular disease.11 
CAVS is characterized by progressive narrowing of the aortic valve resulting in aortic 
stenosis, calcification and thickening of the aortic valves and aortic valve regurgitation.110 
Traditionally, calcified aortic valve stenosis has been associated with normal aging and 
valve degeneration. However, recent studies suggest that CAVS can be attributed to a 
genetic origin. Mutations in Notch1, an important factor that is involved in many 
developmental processes, has been shown to cause aortic valve disease similar to 
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CAVS.111 Notch1 functions by repressing the activities of Runx2, a central transcriptional 
regulator in osteoblast cell fate.111 The origin of calcification in the aortic valve is still 
under debate. Studies have shown that calcification originates from circulating progenitor 
cells that would reside on the aortic valve and differentiate into bone marrow–derived 
type I collagen+ osteocalcin (OCN)+ CD45+ subpopulation of mononuclear adherent cells, 
these cells then cause ossification.112, 113 Another hypothesis is that valvular interstitial 
cells undergo differentiation and they would gain an osteoblast-like phenotype and cause 
calcification.114, 115 It is likely a contribution of both scenarios that result in valve 
calcification. Environmental influences may also play a role in CAVS. Cardiovascular 
risk factors such as smoking, hypercholesterolemia, hypertriglyceridemia, diabetes 
mellitus, and chronic kidney disease all have been shown to contribute to CAVS.116 
Currently, the only clinical treatment for CAVS is valve replacement surgery. Effective 
medical treatments to alter the course of CAVS are non-existent.  
1.10 Nitric Oxide Synthase 
Nitric oxide (NO) is produced from the guanidino group of L-arginine in an 
NADPH-dependent reaction catalyzed by a family of NO synthase (NOS) enzymes in living 
organisms.117, 118 Originally identified as a vasodilatory agent, NO is now recognized as an 
important signalling molecule involved in a wide range of physiological and 
pathophysiological processes including cell growth, apoptosis, antithrombosis, 
neurotransmission, and immunological regulation.118, 119 The wide range of functions and 
physiological importance of NO were recognized by the Nobel committee and awarded the 
1998 Nobel prize of medicine to Drs. Furchgott, Ignarro and Murad for their contributions 
towards the discovery of NO. The vasodilatory function of NO was first discovered by Dr. 
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Furchgott and was termed endothelium-derived relaxing factor (EDRF).120 Later on, EDRF 
was identified as NO by Dr. Ignarro.121 The ultimate signalling of NO through cGMP was 
shown by Dr. Murad.122 There are 3 distinct isoforms of NOS: neuronal NOS (NOS1), 
inducible NOS (NOS2) and NOS3. Each NOS isoform is encoded by a distinct gene and is 
expressed in a variety of tissues and cell types. NO produced from NOS1 and NOS3 is 
involved in intracellular and intercellular signalling, whereas the high output NO produced 
by NOS2 is associated with inflammatory processes.118, 119 NO produced by different 
isoforms of NOS contributes towards signalling in the neuronal, immune, reproductive, 
vascular and most importantly, cardiovascular systems.118, 119 Shear stress induces NOS3 
expression in the cardiovascular system during chick embryonic development.123 In addition 
to shear stress, NOS3 can also be induced and activated by Krüppel-like factor 2 (Klf2), an 
endothelial transcription factor that is crucially involved in vasculogenesis.124, 125 In the 
adult heart, NO released from NOS3 has several major roles including coronary 
vasodilation and tonic inhibition of mitochondrial O2 consumption.118, 126 NO may also play 
a role in the muscarinic-cholinergic inhibition of -adrenergic-stimulated chronotropy,127 
inotropy,126 and atrioventricular nodal conduction. The effects of NO are mediated by the 
cGMP-dependent signaling and protein modification through S-nitrosylation.118, 128 In 
cGMP-dependent signalling, NO would activate downstream guanylate cyclase which leads 
to the production of cGMP. Binding of cGMP to the regulator domain of protein kinase G or 
cGMP dependent protein kinase induces a conformation change which stops the inhibition 
of catalytic core and allows phosphorylation of other downstream proteins.  Protein kinase 
G is a serine/threonine-specific protein kinase that phosphorylates a number of important 
biological targets. 118, 119 These targets drive many cellular processes which may regulate 
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smooth muscle relaxation, platelet function, sperm metabolism, cell division and nucleic 
acid synthesis. Other NO mediated signalling includes S-nitrosylation. This is defined by the 
process of covalent incorporation of NO into thiol groups forming S-nitrosoprotein (SNO). 
118, 125 This modification allows activation or deactivation of proteins. The activation or 
deactivation of proteins depends on the type of protein. For example, caspases that are 
important in cellular apoptosis have been shown to be inhibited by SNO. On the other hand, 
metalloproteinases which are important in degrading extracellular proteins are activated by 
SNO. SNO is an extremely complex process which remains poorly understood.  
1.11 NOS3 Expression in the Embryonic Heart 
NOS3 is expressed in the heart early during mammalian embryonic development. 
129,130 Although this expression is not restricted in the heart, other organs such as lung, 
liver, gastrointestinal tract, reproductive organs and brain hippocampus all have NOS3 
expression. Immunohistochemical analysis in mice using NOS3 specific antibodies 
revealed that the heart, including cardiomyocytes, start to express NOS3 at E9.5 and 
expression remains high up to E13.5. Starting from E14.5, levels of NOS3 expression 
decrease in both atria and ventricles. After E19.5 low NOS3 levels are still detectable and 
this level of NOS3 expression in the myocardium remains to adulthood.130 Parallel with 
NOS expression, there are also changes in guanylate cyclase and cGMP production 
indicating the NO-cGMP signaling pathway in the heart development. The production of 
NO from NOS3 regulates the voltage-dependent L-type Ca2+ current in cardiomyocytes 
during early embryonic development and has been shown to promote cardiomyogenesis 
from mouse embryonic stem cells.130-132 It is important to note that although NOS1 and 
16 
 
NOS2 are expressed during cardiogenesis, NOS1 and NOS2 knockout mice have normal 
cardiac phenotype.  
1.12 NOS3 and Heart Development 
Septal defects are the most common cardiac malformations in humans.133 However, 
the molecular mechanisms that govern the formation of atrial and ventricular septum remain 
poorly understood. In recent years, through the use of genetic knockout mice, several 
transcriptional factors including Gata4, Nkx2.5 and Tbx5 have been identified to be critical 
in the development of atrial and ventricular septum.133, 134 In addition, mutations in these 
factors are associated with congenital septal defects in humans.133, 135 Feng et al. show that 
deficiency in NOS3 results in congenital septal defects and heart failure, and is accompanied 
by 85% postnatal mortality.136 All mortalities occur within the first 7 days after birth. Post-
mortem examination show NOS3-/- mice have a high incidence of congenital septal defects 
with 64% atrial septal defects and 11% ventricular septal defects. Congenital septal defects 
can be a result of improper fusion of the atrioventricular cushions during embryonic heart 
development. In addition, increases in apoptosis in atrioventricular cushions can also 
contribute to congenital septal defects.137, 138 In order to investigate the role of NOS3 in 
septal development, myocardial apoptosis was analysed in WT and NOS3-/- hearts at E12.5, 
a crucial time point in which the atrioventricular cushions start to fuse together. Feng et al. 
show that there is an overall increase in the apoptotic activities in the NOS3-/- compared with 
WT hearts as measured by both caspase 3 activity and cytosolic DNA fragments. In order to 
determine the apoptotic activity in the atrioventricular cushion, TUNEL staining was used. 
Feng and colleagues show that there is a significant increase in the apoptotic activity in the 
region of the atrioventricular cushions, which may contribute at least in part to the increased 
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incidence of congenital septal defects seen in the postnatal day 1 NOS3-/- mice.136 Low 
levels of NO produced by NOS3 inhibit apoptosis via S-nitrosylation of caspase-3, a critical 
protease responsible for the execution of apoptosis, and by promoting expressions of 
cytoprotective proteins including heme oxygenase-1, heat shock protein 70 (HSP70) and 
metallothionein.119 In addition, NO has also been shown to inhibit mitochondrial 
cytochrome c release and decrease permeability transition pore opening via mitochondrial 
membrane depolarization and inhibition of Ca2+ accumulation.139 These mechanisms may 
explain the increased apoptosis in the embryonic heart of NOS3-/- mice.  
Many factors may regulate the expression of NOS3 during embryonic heart 
development. Bio-informatics analysis of the mouse NOS3 locus showed three canonical 
Tbx5 binding sites, two of which are flanked by Gata binding site that binds to both Tbx5 
and Gata4 with high affinities.140 Using genetically modified animals, Nadeau et al. showed 
that endocardial specific knock-down of Tbx5 results in atrial septal defects with a 100% 
penetrance, suggesting Tbx5, a potential upstream regulator of NOS3, is also crucial in the 
proper formation of the atrial septum.140 Furthermore, compound haploinsufficiency of 
Tbx5 and NOS3 exacerbates the cardiac phenotype caused by deletion of a single Tbx5 
allele from endocardial cells, suggesting that NOS3 may be a genetic modifier of Tbx5.140 
Interestingly, decreases in enzyme activity and NO production in an 894G>T polymorphism 
of the NOS3 gene are associated with increased risks of CHD.141-143 Environmental factors 
and maternal conditions including psychological stress, hypertension and diabetes have been 
linked to increased risks of congenital heart disease.13  It has been shown that these 
environmental and maternal conditions can decrease NOS3 expression and/or activity.144, 145 
The finding that NOS3, an enzyme that may be  regulated by environmental conditions, 
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interacts with Tbx5, suggests the importance of gene–environment interactions in the setting 
of congenital heart disease and may help to explain the variable expressivity of the same 
mutation among affected family members and the complex inheritance patterns of 
congenital heart disease.140, 146 
In addition to the congenital septal defect, cardiac hypertrophy is also seen in   
NOS3-/- mice at postnatal day 0.136 From gross inspection and quantification, the NOS3-/- 
hearts are significantly larger than WT hearts. In order to determine if the cardiac function is 
impaired, in vivo heart shortening was determined in the anesthetized P1 mice using 
ultrasound crystals that were placed on the surface of the heart. Feng et al. show that percent 
shortening is significantly decreased in NOS3-/- compared to WT hearts. In addition, LV 
chamber size is significantly increased in NOS3-/- hearts. Furthermore, severe pulmonary 
congestion with focal alveolar edema is also seen in NOS3-/- mice at P1. Cardiac dysfunction 
and pulmonary congestion are typical clinical manifestations of heart failure. These results 
suggest that the higher mortality in postnatal NOS3-/- mice is likely due to the development 
of heart failure after birth.136 However, the exact cause of heart failure remains unclear. 
Congenital heart defects and decreased capillary density in the heart and lungs may 
contribute to the development of heart failure after birth in NOS3-/- mice.147-150 
1.13 NOS3 and Its Upstream Activators  
In addition to transcription factors, NOS3 activity and expression are also 
regulated by a serine/threonine kinase Akt, also known as protein kinase B (PKB).151-153 
Akt is an important mediator of phosphatidylinositol-3 kinase (PI3K) signaling that 
regulates a wide variety of cellular functions including survival, growth, proliferation, 
glucose uptake, metabolism, and angiogenesis.154 The effects are achieved through the 
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regulation of genes and proteins involved in these processes including NOS3.155, 156 There 
are three Akt isoforms, Akt1, Akt2 and Akt3, which have similar structures and 
molecular sizes (57 kDa). All three Akt isoforms are expressed in the embryo starting 
from two-cell stage to virtually every organ during embryonic development. Inhibition of 
PI3K or Akt attenuates cardiomyocyte differentiation in embryonic stem cells, suggesting 
a critical role of PI3K/Akt signaling in early stage cardiomyocyte differentiation.157 Three 
Akt isoforms have similar but yet distinct physiological roles. Targeted disruption of the 
Akt1 gene in mice results in growth retardation with 20% reduction in body size as well 
as septal defects.158, 159 Akt2 knockout mice display insulin resistance and growth 
retardation while Akt3 knockouts show reduced brain size.160, 161 It is worth noting that 
the septal defects seen in the Akt1-/- resembles to that of the NOS3-/- mice.136, 158 Akt1-/- 
mice showed perimembranous and muscular ventricular septal defects as well as atrial 
septal defects which are similar to those of NOS3-/- mice. 
The effect of Akt is mediated in part by upregulation of Gata4 expression via 
phosphorylation of Gsk-3.162 Gsk3 inhibits the DNA binding activity of Gata4. Upon 
phosphorylation by Akt, Gsk3 exits the nucleus, which curtails the inhibitory effect of 
Gsk3 on Gata4, leading to increases in Gata4 activation.162 Gata4 is a transcriptional 
factor that belongs to an evolutionarily conserved family of zinc finger-containing proteins, 
which has 6 members.163 Gata-1, -2 and -3 are expressed in hematopoietic stem cells while 
Gata-4, -5 and -6 are expressed in various mesoderm- and endoderm-derived tissues 
including the heart, liver, lung, gonad, and gut. Gata4 is a critical regulator of early 
cardiogenesis. Homozygous Gata4 knockout mice die at E9.5 and display defects in heart 
and foregut morphogenesis.45 Using tetraploid embryo complementation, Zhao et al. (2008) 
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showed that Gata4 controls cardiomyocyte differentiation in mice. It appears that in the 
Gata4-/- mice, initiation of cardiomyocyte differentiation starts normally, but progenitors 
cannot differentiate into terminal cardiomyocytes as shown by the lack of smooth muscle 
actin, myosin heavy chain or sarcomeric actin staining.164 In humans, heritable mutations of 
GATA4 result in congenital heart defects including, atrial septal defects, ventricular septal 
defects, atrioventricular septal defects, pulmonary valve thickening or insufficiency of 
cardiac valves.135 Interestingly, the promoter region of NOS3 contains Gata4 binding 
sites.140 Studies have shown that Gata4 binds to these sites and increases NOS3 promoter 
activity,165 suggesting Gata4 also serves as an upstream activator of NOS3. 
1.14 NOS3 and Its Downstream Effectors  
A classic pathway by which NO mediates its biological function is through 
cGMP-dependent protein kinase G (PKG) signaling.166 Activation of PKG has been 
shown to up-regulate varies downstream transcription factors that are important in heart 
development.167, 168 Thus, a deficiency in NOS3 decreases NO and cGMP production, and 
may lead to decreased PKG activation and down-regulation of transcription factors in 
heart development such as Gata4. Gata4 is a master regulator of heart development, and 
controls the expression of many growth factors including VEGF, FGF and EPO, that are 
important for coronary vessel formation and heart formation.169-171 NO can exert its 
biological effect through other mechanisms. First, NO can cause oxidation of iron-
containing proteins such as ribonucleotide reductase. Ribonucleotide reductase is an 
important enzyme in formation of formation of deoxyribonucleotides from 
ribonucleotides. In addition, NO can activate proteins via sulfhydryl group 
nitrosylation.172 Nitrosylation involves the covalent binding of a nitric oxide into thiol 
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groups, to form S-nitrosothiol (SNO). S-nitrosylation has since been shown to be 
ubiquitous in biology.173-175 Dysfunction in S-nitrosylation has been associated with 
cardiovascular disease, Parkinson's disease, Alzheimer's disease and Amyotrophic Lateral 
Sclerosis (ALS). Finally, there is an emerging role of S-nitrosylation in cancer 
biology.176-179 
1.15 NOS3 Promotes Cardiomyocyte Proliferation  
NOS3 is important to cardiomyocyte proliferation during early postnatal cardiac 
development.180, 181 To assess proliferation, cardiomyocytes were isolated from neonatal 
mice born within 24 hours and cultured for up to 96 hours. Cell proliferation was 
determined by bromodeoxyuridine (BrdU) incorporation and cell counts. Lepic et al. 
showed that cultured NOS3-/- cardiomyocytes displayed fewer cells and lower BrdU 
incorporation compared with WT cardiomyocytes.181 In order to analyze if the decreased 
cardiomyocyte proliferation is related to the level of NO produced by NOS3, NOS3-/- and 
WT cardiomyocytes were treated with an NO donor and a NOS inhibitor, respectively. 
Treatment with the NO donor diethylenetriamine NONOate increased BrdU 
incorporation and cell counts in NOS3-/- cardiomyocytes. Inhibition of nitric oxide 
synthase activity using NG-nitro-L-arginine methyl ester (L-NAME) decreased the level 
of BrdU incorporation and cell counts in WT cardiomyocytes. Furthermore, to investigate 
cardiomyocyte proliferation in vivo, neonatal mice were treated with BrdU. Deficiency in 
NOS3 significantly decreased BrdU labeling indexes in neonatal hearts.181 These data 
suggest that NO production from NOS3 is necessary for postnatal cardiomyocyte 
proliferation, providing a crucial role of NOS3 during postnatal heart development. 
However, despite decreases in cell proliferation, the overall size of the heart is enlarged 
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in NOS3-/- as compared to WT mice (Figure 1A). This is probably due to the fact that 
cardiomyocyte proliferation is low and cardiac hypertrophy is the predominant response 
during early postnatal heart development.182, 183 
1.16 NOS3 Promotes Postnatal Heart Maturation 
 The fetal and neonatal hearts develop through both hyperplasia and hypertrophy, 
which are increases in cell number and cell mass, respectively.183, 184 During early 
postnatal cardiac development, proliferation still occurs, albeit at a much lower level 
compared to fetal hearts. However, shortly after birth cardiomyocytes undergo 
binucleation, accompanied by a cessation of proliferation and a complete switch to 
hypertrophic growth.182, 183 In rodents this transition from hyperplastic growth to 
hypertrophic growth occurs within approximately 1-2 weeks after birth.182, 183 Embryonic 
heart development is characterized by the expression of cardiac specific proteins such as 
atrial natriuretic peptide (ANP) and proteins that form the contractile apparatus such as 
myosin heavy chain (MHC). After birth, as the heart gradually gains a mature phenotype, 
ANP expression is decreased and there is also a switch from beta to alpha isoform of 
MHC in cardiomyocytes.185 In the mature myocardium, α-MHC is the predominant 
isoform.186, 187 Lepic et al confirmed these postnatal changes in the WT mice and showed 
that cardiac ANP expression is progressively decreased from postnatal day 1 to day 7 
while the expression of α-MHC is increased.181 On the other hand, in the NOS3-/- hearts, 
the levels of ANP remain high and the levels of α-MHC are significantly decreased at 
postnatal day 7, suggesting that NOS3 deficiency disturbs the normal temporal changes of 
ANP and α-MHC during postnatal heart development. These data support the notion that 
NOS3 plays an important role in promoting postnatal heart maturation.181 However, the 
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underlying molecular mechanisms responsible for these changes are not fully understood. 
Studies have shown that NF-κB, a transcription factor that is involved in inflammation, 
cell survival and growth, can modulate the expression of ANP and α-MHC.188, 189 In 
addition, NO can increase or decrease the expression of NF-κB depending on its 
concentrations and the cell types.190, 191 It is possible that NO produced from NOS3 may 
act through the NF-κB pathway to modulate expression of ANP and α-MHC in postnatal 
hearts.  
1.17 NOS3 and Myocardial Capillary Development 
NOS3 is crucial in the formation of capillaries and angiogenesis.149 To investigate 
the role of NOS3 in capillary development, myocardial capillary densities were measured 
morphometrically in P1 mouse hearts. Zhao et al. showed that myocardial capillary 
densities were decreased in NOS3-/- compared with WT mice.149  Next, in vitro tube 
formation of cardiac endothelial cells was investigated on Matrigel. Lack of NOS3 
impaired tube formation of endothelial cells. In order to analyze if the decreased tube 
formation is related to the level of NO produced by NOS3, NOS3-/- and WT endothelial 
cells were treated with an NO donor and a NOS inhibitor, respectively. In vitro tube 
formation was inhibited by NG-nitro-L-arginine methyl ester (L-NAME, a NOS inhibitor) 
in wild-type cells and restored by a NO donor, diethylenetriamine-NO, in NOS3-/- cells.  
In addition, angiogenesis was evaluated via implanting Matrigel in the myocardium of 
the adult heart. Following 3 days of implantation, significant angiogenesis is seen in the 
implanted Matrigel in WT mice. The angiogenic response was significantly decreased in 
the NOS3-/- mice. These data show that deficiency in NOS3 impairs myocardial 
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angiogenesis and capillary development, suggesting an important role of NOS3 in 
myocardial capillary development.149   
1.18 NOS3 and Aortic Valve Development 
 The morphogenesis of the heart valves occurs concomitantly with changes in the 
cardiac morphology and in a complex process that includes initiation, cushion formation, 
elongation, valve remodeling and maturation.7, 34 Valve development is initiated during 
cardiac looping when the primary myocardium secretes a hyaluronan-rich matrix called 
cardiac jelly that projects into the lumen at the atrioventricular junction and the outflow 
tract at E9.0 in mice. The underlining myocardial cells produced factors including bone 
morphogenetic protein-2 (BMP2), BMP4 and transforming growth factor (TGF)-, which 
activate the overlaying endocardium. At E10.5, the activated endocardial cells undergo 
EMT to become spindle shaped migratory cells (mesenchymal phenotype) and invade the 
cardiac jelly. Proliferation of the mesenchymal cells and matrix deposition extend the 
cushions into the cardiac lumen and form primordium of each distinct valve. This is then 
followed by elongation and remodeling/thinning of the valve primordial at E12.5, which 
leads to the gradual maturation of the valves that are rich in elastin, fibrillar collagen and 
proteoglycans. During valve remodeling, cell proliferation decreases, and subsequently 
there is little to no proliferation of valve interstitial cells in the adult. Formation of four 
distinct valves is a result of septation of the outflow tract into aorta and pulmonary trunk 
giving rise to aortic and pulmonary valves, and fusion of the atrioventricular canal 
endocardial cushions giving rise to mitral and tricuspid valves.29  
Normal aortic valves have 3 distinct cusps (or leaflets) while bicuspid aortic 
valves have only 2 cusps.6 Lee et al. were the first to show that deficiency in NOS3 
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results in the formation of bicuspid aortic valves. The adult NOS3-/- mice had high 
incidences (5/12, 42%) of bicuspid aortic valves.192 Subsequent studies confirmed 
bicuspid aortic valves with an incidence of about 30% in NOS3-/- mice.193 In patients with 
bicuspid aortic valves, the common subtypes are fusion of right and left coronary leaflets 
(R-L) as well as fusion of right and non-coronary leaflets (R-N).6, 194 In NOS3-/- mice, the 
bicuspid aortic valve is the R-N subtype in which the left leaflet develops normally.193 
Data from the Feng lab also showed that NOS3-/- mice have bicuspid aortic valves.195 
Furthermore, these mice have significant aortic regurgitation at postnatal day 1 as 
demonstrated by pulsed-wave Doppler and color flow Doppler echocardiography. The 
data is consistent with aortic regurgitation seen in patients with bicuspid aortic valves.196 
Notch signalling is essential for early embryonic development of aortic valves and 
postnatal repression of calcium deposition in the aortic valves. Mutations in the NOTCH1 
gene cause autosomal-dominant anomalies of aortic valves and severe valve calcification 
in humans.111 In mice, Notch1 transcripts are the most abundant in the developing aortic 
valves. Furthermore, Notch1 inhibits the activity of Runx2, a central transcriptional 
regulator of osteoblast cell fate. Thus, decreases in Notch1 signaling result in 
developmental defect in the aortic valve and postnatal calcification that causes 
progressive aortic valve disease.111 Additionally, Notch signalling is also required for the 
EMT process in endocardial cushions during early valve development.197  Interestingly, 
recent studies have shown that Notch signalling activates NOS3 and its downstream 
target, soluble guanylyl cyclase via PI3K/Akt pathway.37 Therefore, NOS3 is likely a 
potential downstream target of Notch signalling that governs aortic valve development 
and postnatal remodeling.  
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1.19 NOS3 and Thrombosis 
The role of NO in thrombosis formation has been investigated in animal models 
using NOS inhibitors and its substrate L-arginine. Stagliano et al. have shown infusion of 
L-NAME, a NOS inhibitor, caused an increase in platelet adhesion in a rat brain stroke 
model.198 In a glomerular thrombosis model, administration of endotoxin increased NO 
production and this effect was inhibited by infusion of L-NAME. Kidneys from rats 
given endotoxin and L-NAME showed enhanced thrombosis in glomeruli as compared 
with control with either L-NAME or endotoxin treated alone.199 In a canine model of 
coronary occlusion, L-arginine treatment increased lysis of thrombus in the coronary 
arteries and inhibited platelet aggregation ex vivo.200 The importance of NOS3 in the 
prevention of thrombosis formation has also been demonstrated in the NOS3 knockout 
mice.201 These mice showed increased susceptibility to thrombosis, stroke and 
atherosclerosis.202-205 Exogenously, treatment with a NO-donor inhibited the upregulation 
of platelet surface glycoprotein including selectins and integrins, which are important for 
platelet aggregation.206 The molecular basis of the NO effect on platelets has been mainly 
attributed to cGMP dependent signalling.207-209 The increased production of cGMP leads 
to protein kinase G stimulation which results in fibrinogen binding to calcium-dependent 
heterodimeric complex of glycoproteins.207-209 This glycoprotein complex serves as an 
activation-dependent receptor for adhesive proteins such as fibrinogen.210 Binding of 
fibrinogen to glycoproteins mediated platelet aggregation which is crucial in thrombus 
formation. Decreased NO levels are also associated with thrombosis in human 
diseases.211, 212 It is well known that thrombosis is a common cause of myocardial 
infarction and unstable angina, and platelets from these patients show increased surface 
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expression of selectins and active glycoproteins.213, 214 Interestingly, platelets isolated 
from these patients produce less NO compared to patients with stable coronary artery 
disease.215 The role of human NOS3 polymorphisms in thrombosis has recently been 
studied.216-219 It has been shown that NOS3 polymorphism is associated with lower 
platelet NO production, higher superoxide release and an increased risk of myocardial 
infarction, hypertension, stroke, and stenosis of arteries.216-220 Taken together, these 
results suggest that NOS3 variants may influence thrombotic susceptibility in humans.  
1.20 NOS3 and Aortic Valve Calcification 
Aortic valve calcification can occur spontaneously with increasing age, 
atherosclerosis and disease conditions such as diabetes and renal disease.221 It has been 
shown that NO inhibits calcification of vascular smooth muscle cells and differentiation 
of VSMCs into osteoblastic cells via inhibition of  transforming growth factor-β (TGF-
β)-induced phosphorylation of Smad2/3 and expression of TGF-β-induced genes such as 
plasminogen activator inhibitor-1.222  An inhibitor of cGMP dependent protein kinase 
increased osteoblastic differentiation and calcification of vascular smooth muscle cells. 
222 In addition, atorvastatin, a statin drug, inhibits calcification and enhances NO 
production in the hypercholesterolaemic aortic valves.223  NOS3 protein concentrations 
were increased in the atorvastatin treated group. Serum nitrite concentrations were 
decreased in the hypercholesterolaemic animals and increased in the group treated with 
atorvastatin. 223  These data suggest that NOS3 may act through TGF-β to prevent 
calcification of vascular smooth muscle cells and the degree of calcification may relate to 
the amount of NO produced. Although the precise role of NOS3 on aortic valve 
calcification is not well understood, Bosse et al. have suggested that NOS3 signalling can 
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regulate Notch1, a key molecule in aortic valve calcification and genetically linked to 
human calcific aortic valve disease.111 They have shown that calcification of aortic valve 
interstitial cells can be prevented or accelerated by gain or loss of NO, respectively. In 
addition, overexpression of Notch1 can slow down the progression of valvular 
calcification induced by NO inhibition.224 These results suggest that NOS3 do play an 
important protective role against aortic valve calcification.  
1.21 Summary of Heart Defects in NOS3-/- mice 
Cardiac NOS3 expression starts early in cardiogenesis at E9.5 and remains high 
until E13.5. This also coincides with the crucial period of rapid heart development and 
formation of coronary arteries and aortic valves. Deficiency in NOS3 results in cardiac 
hypertrophy, congenital septal defects, and postnatal heart failure.136, 225 In addition, 
myocardial capillary densities are decreased in NOS3-/- mice. Furthermore, deficiency in 
NOS3 results in high incidence of bicuspid aortic valves. These data suggest that NOS3 
plays a critical role in embryonic heart development and morphogenesis of aortic valves 
and possibly coronary arteries (Figure 1.1). Although how lack of NOS3 leads to these 
cardiac phenotypes is not completely understood, possible mechanisms may include 
increases in apoptosis, decreases in cell proliferation, changes in gene expression, and 
decreases in EPDC migration and EMT. We anticipate that studies on these mechanisms 
of NOS3 during embryonic heart development may lead to therapeutic strategies in the 
prevention and treatment of congenital heart disease.  
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Figure 1.1. NOS3 is crucial during heart development. NO produced from NOS3 may 
promote coronary artery development, proper septal formation, proper valve formation, 
capillary development and cardiomyocyte maturation. 
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1.22 Rationale and Hypotheses 
Overall Hypothesis: 
Deficiency of NOS3 results in hypoplastic coronary arteries, atrioventricular valve 
insufficiency, and aortic valve calcification and thrombosis.  
Overall Objectives (Figure 1.2): 
1. Investigate the role of NOS3 in fetal coronary artery development. 
2. Investigate the role of NOS3 in fetal atrioventricular valve development. 
3. Investigate the role of NOS3 in maintaining normal aortic valve structure and 
function in adulthood and aging.  
 
Study 1. Role of NOS3 in coronary artery development  
Rationale:  
NOS3 is expressed in the embryonic heart at E9.5. Studies have shown that NO 
production from NOS3 is critical in cardiogenesis.132 Previous studies have demonstrated 
that NOS3 plays an important role in embryonic heart development.136, 180, 181 
Furthermore, NOS3 promotes cardiomyocyte proliferation and protects cardiomyocytes 
from apoptosis. Deficiency in NOS3 resulted in embryonic and postnatal abnormalities in 
heart development.136 NO from NOS3 is an important mediator of vasculogenesis and 
angiogenesis. Additionally, studies have shown that development of myocardial 
capillaries is impaired in NOS3-/- mice.149 Coronary artery development is a complex 
process, which involves the migration of PEO to the looping heart, and subsequent 
migration and differentiation of epicardium-derived mesenchymal cells.30, 31 The 
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molecular mechanisms regulating coronary artery development are still not well 
understood.  
Hypothesis:  
Deficiency in NOS3 impairs coronary artery development.  
Objectives:  
1. To analyze coronary artery development in NOS3+/+, NOS3-/-, NOS3Tg;NOS3-/- 
and NOS3Tg mice at E15.5 and P0.  
2.  To identify the cause of death in the NOS3-/- neonates. 
3. To understand the signaling mechanisms by which NOS3 controls coronary artery 
development. 
 
Study 2.  Role of NOS3 in atrioventricular valve development 
Rationale:  
 NOS3 is important for embryonic heart development. Deficiency in NOS3 leads 
to congenital septal defect, bicuspid aortic valves and coronary artery malformation.136, 
192, 225 The temporal expression pattern of NOS3 peaks during atrioventricular valve 
formation, suggesting that NOS3 may participate in the development of the 
atrioventricular valves. However, the role of NOS3 in atrioventricular valve formation 
and endothelial to mesenchymal transition is not known. 
Hypothesis:  
Deficiency in NOS3 impairs atrioventricular valve formation and endothelial to 
mesenchymal transition.  
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Objectives:  
1. To assess atrioventricular valves in NOS3+/+, NOS3-/-, NOS3Tg;NOS3-/- and 
NOS3Tg mice at postnatal day 0. 
2. To determine if atrioventricular valve defects in NOS3-/- mice result in functional 
deficits. 
3. To understand the role of NOS3 in the formation of atrioventricular valves. 
 
Study 3. Lack of NOS3 results in thrombosis, calcification and dysfunction of aortic 
valve  
Rationale:  
The spontaneous formation of a thrombus on the aortic valve is extremely rare in 
humans; there are only less than a dozen of case reports in the literature.100-109 However, 
aortic valve thrombosis is extremely dangerous, as it could lead to embolization, and 
subsequent cerebrovascular events such as stroke, myocardial infarction and death.101-104, 
108 These patients are limited to surgery as it is the only available and effective treatment. 
The cause of aortic valve thrombosis remains unclear. Mutations in Notch1, an important 
factor that is involved in many developmental processes, have been shown to cause aortic 
valve disease similar to calcified aortic valve stenosis.111 Additional evidence showed 
that NOS3 acts upstream of Notch1 and regulate its expression.224 This would suggest 
that disruption in NOS3 signalling would also result in phenotypes similar to that of 
Notch1 mutation. Studies have suggested that endothelial damage in bicuspid aortic valve 
or calcific aortic valve disease could potential result in the formation aortic valve 
thrombosis. 157-160, 164 To our knowledge, spontaneous aortic valve thrombosis has never 
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been studied in an animal model.  Study 3 investigated the role of NOS3 in normal 
maintenance of aortic valve function and its deficiency results in aortic valve thrombosis, 
dysfunction and calcification in adulthood and aging. 
Hypothesis:  
Deficiency in NOS3 leads to aortic valve thrombosis, dysfunction and calcification in 
aging mice. 
Objectives:  
1. To investigate the role of NOS3 in the formation of aortic valve thrombosis in 
aging mice. 
2. To assess aortic valve function in vivo in NOS3+/+ and NOS3-/- mice at 1, 3, 5, 9 
and 12 Months. 
3. To analyze the degree of calcification and fibrosis of aortic valve leaflets in 
NOS3+/+ and NOS3-/- mice. 
4. To understand the role of NOS3 in aortic valve calcification. 
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Figure 1.2 Summary of studies 1, 2 and 3 on the role of NOS3 in embryonic heart 
development and adult aortic valve function.  
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2 Chapter 2 
Nitric oxide synthase-3 deficiency results in hypoplastic coronary arteries and 
postnatal myocardial infarction 
 
 
 A version of this chapter has been published in European Heart Journal 2014, 35(14): 
920-31. 
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 “Nitric oxide synthase-3 deficiency results in hypoplastic coronary arteries and postnatal 
myocardial infarction.”  
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2.1 CHAPTER SUMMARY 
Aims: Hypoplastic coronary artery disease is a rare congenital abnormality that is 
associated with sudden cardiac death.  However, molecular mechanisms responsible for 
this disease are not clear. The aim of the present study was to assess the role of nitric 
oxide synthase-3 (NOS3) in the pathogenesis of hypoplastic coronary arteries.  
Methods and Results: Wild-type (WT), NOS3-/- and a novel cardiac specific NOS3 
overexpression mouse model were employed. Deficiency in NOS3 resulted in coronary 
artery hypoplasia in fetal mice and spontaneous myocardial infarction in postnatal hearts. 
Coronary artery diameters, vessel density and volume were significantly decreased in 
NOS3-/- mice at postnatal day 0. In addition, NOS3-/- mice showed a significant increase 
in ventricular wall thickness, myocardial volume and cardiomyocyte cell size compared 
with WT mice. Lack of NOS3 also down-regulated the expression of Gata4, Wilms 
tumor-1, vascular endothelial growth factor, basic fibroblast growth factor and 
erythropoietin, and inhibited migration of epicardial cells. These abnormalities and 
hypoplastic coronary arteries in the NOS3-/- mice were completely rescued by the cardiac-
specific overexpression of NOS3.  
Conclusion: NOS3 is required for coronary artery development and deficiency in NOS3 
leads to hypoplastic coronary arteries. 
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2.2 INTRODUCTION 
Congenital coronary anomalies affect up to 5% of the general population.1, 2 Most of 
these do not have clinical signs or symptoms, and are often unrecognized. However, severe 
congenital coronary artery malformation is associated with myocardial ischemia, infarction 
and sudden cardiac death.3 Hypoplastic coronary artery disease (HCAD), a rare congenital 
coronary abnormality, is defined by malformation of one or more major branches of the 
coronary arteries with a marked decrease in luminal diameter and length.4-6 HCAD can be 
asymptomatic, but is often associated with myocardial infarction and sudden cardiac death 
under stress, such as during intense physical activity.3, 7 However, the molecular 
mechanisms responsible for embryonic development of HCAD are still unknown.  
Nitric oxide (NO) is produced from the guanidino group of L-arginine in an 
NADPH-dependent reaction catalyzed by a family of NO synthase (NOS) enzymes.8 
Originally identified as a vasodilatory agent, NO is now recognized as an important 
signaling molecule involved in a wide range of physiological processes including 
apoptosis, angiogenesis and cell growth.8, 9 There are 3 distinct isoforms of NOS: 
neuronal NOS (nNOS, NOS1), inducible NOS (iNOS, NOS2) and endothelial NOS 
(eNOS, NOS3). Interestingly, NOS3 is expressed in cardiomyocytes during early 
mammalian embryonic heart development.10 Immunohistochemical analysis revealed that 
the heart starts to express NOS3 at E9.5 and the expression remains high until E13.5. 
Starting from E14.5 the levels of NOS3 expression decreases in both atria and 
ventricles.10 The expression of NOS3 in the heart peaks during coronary artery 
development,10, 11 suggesting its potential importance. However, the role of NOS3 in 
embryonic coronary artery development is still not clear.  
52 
 
The signaling milieau within the developing heart is critical to coronary 
vasculogenesis.11 Transcription factors such as Gata4 and Wilms tumor-1 (Wt1),12, 13 as 
well as growth factors including vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (FGF) and erythropoietin (EPO) 14, 15 are essential in the 
formation of coronary arteries.11, 15  We have previously shown a key role of NOS3 to 
capillary vessel development in the heart.16 In the present study, we hypothesized that 
NO production from NOS3 within the embryonic heart is a critical signaling molecule in 
the development of coronary arteries and deficiency in NOS3 results in hypoplastic 
coronary arteries. 
2.3 METHODS 
2.3.1 Animals 
Breeding pairs of NOS3-/- (stock No. 002684) and wild-type C57BL/6 (NOS3+/+) 
mice were purchased from Jackson Laboratory (Bar Harbor, Maine). A breeding program 
was carried out to produce neonates. Genotyping of NOS3-/- and NOS3+/+ mice was 
performed by a polymerase chain reaction (PCR) method using genomic DNA prepared 
from tail biopsies. A timed breeding program was carried out. Vaginal plug was 
monitored in the morning of each day and a plug was considered 0.5 days into pregnancy. 
Embryonic hearts were collected at E12.5, E15.5 and postnatal day 0 (P0). All procedures 
involving mouse husbandry and manipulation were in accordance with the guidelines of 
the Canadian Council of Animal Care and approved by the Animal Use Subcommittee at 
the University of Western Ontario, Canada. 
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2.3.2 Generation of Human NOS3 Transgenic Mice  
A new line of cardiac-specific mice overexpressing human isoforms of NOS3 
(NOS3Tg) was generated. Briefly, human NOS3 complementary DNA was inserted into 
the β-myosin heavy chain promoter expression vector to permit the expression of human 
NOS3 only during embryonic development and specifically in the heart. Genotypes were 
identified by PCR using genomic DNA from tail biopsies. Primer sequence is shown in 
Table 1. Relative protein expression of varies genotypes were done via western blotting 
and immunohistochemical staining. 
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Table 2.1 Gene name, accession number and primers used. 
Gene Accession # Primer Sequence  
Hu-NOS3 NM_000603.3 Sense: 5’ CTC GTG TGA AGA ACT GGG AGG T 3’ 
Antisense: 5’ GTG GCA TAC TTG ATG TGG TTG 3’ 
28S NR_003279.1 Sense: 5’ TTG AAA ATC CGG GGG AGA G 3’ 
Antisense: 5’ ACA TTG TTC CAA CAT GCC AG 3’ 
 Gata4 NM_008092.3 Sense: 5’ CAC TAT GGG CAC AGC AGC TC 3’  
Antisense: 5’ GCC TGC GAT GTC TGA GTG AC 3’ 
VEGFa NM_001025250.2 Sense: 5’ GAT TGA GAC CCT GGT GGA CAT C 3’ 
Antisense: 5’ TCT CCT ATG TGC TGG CTT TGG T 3’ 
FGF NM_008006.1 Sense: 5’ CAA GGG AGT GTG TGC CAA CC 3’  
Antisense: 5’ TGC CCA GTT CGT TTC AGT GC 3’ 
EPO NM_007942.2 Sense 5’ GGA ATT GAT GTC GCC TCC AG 3’  
Antisense: 5’ GCA GCA GCA TGT CAC CTG TC 3’ 
Wt1 NM_144783.2 Sense: 5’ GAT GTG CGG CGT GTA TCT GG 3’ 
Antisense: 5’ GCT GGT CTG AGC GAG AAA ACC T 3’ 
 
2.3.3 ECG Monitoring 
Short-term monitoring of ECG limb lead was performed in anesthetized mice 
with needle electrodes inserted subcutaneously. ECG was recorded with Powerlab Chart 
5.0 (AD Instruments, Colorado Springs, CO). 
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2.3.4 TTC Staining 
Neonatal hearts were first dissected out of the body, cut in half and washed in 
PBS to remove blood. Next, they were incubated in 1% TTC solution at room 
temperature for 1 hour. Finally, images are taken on a microscope for macro samples 
(Discovery V8., Zeiss, Germany). 
2.3.5 Three-Dimensional Reconstructions and Histological Analysis 
Three-dimensional (3D) reconstructions of the heart and coronary arteries were 
performed using α-smooth muscle actin stained serially sections of P0 and E15.5 hearts 
through the AMIRA® software (Template Graphics Software, USA). Briefly, stained 
serially sections were imaged (Observer D1, Zeiss, Germany). These images were then 
used for 3D reconstructions of the heart and measurements of coronary artery diameter, 
abundance and myocardial wall thickness. All measurements were made at similar 
anatomical location to ensure consistency. Calculations of myocardial and coronary 
artery volume were made using the AMIRA® program. 
2.3.6 Ex vivo Heart Cultures 
E12.5 NOS3+/+ and NOS3-/- hearts were explanted and cultured in M199 medium 
(Sigma-Aldrich, USA). Hearts were stabilized for 2 hours prior to any treatment. Both 
NOS3+/+ and NOS3-/- hearts were beating throughout the entirety of the experiment. 
NOS3+/+ and NOS3-/- hearts were treated with 100 µM ODQ (Sigma-Aldrich Chemie, 
USA) and 2 mM 8-Bromo-cGMP (Sigma-Aldrich Chemie, USA), respectively for 6 
hours. Hearts were then collected and mRNA levels of Wt1 and Gata4 were analyzed by 
real time RT-PCR. 
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2.3.7 Co-culture of EPDCs and Cardiomyocytes  
E13 eGFP+ hearts were planted on a 35 mm petri dish for 3 days to allow 
outgrowth of epicardial cells, which are epicardial-derived cells (EPDCs). After 3 days, 
the hearts were removed and eGFP+ EPDCs were cultured for 3 more days prior to co-
culture with NOS3+/+ or NOS3-/- cardiomyocytes. NOS3+/+ and NOS3-/- cardiomyocytes 
were isolated according to previous protocol with the following modifications. E13 
NOS3+/+ and NOS3-/- embryos were collected and hearts were carefully dissected out of 
the embryo. The co-culture system functions similar to a wound healing assay system 
(Fig. 2.8A). Cardiomyocytes isolated from E13 NOS3+/+ and NOS3-/- mice were plated on 
the inside of the barrier overnight with or without the treatment of adenoviral NOS3 or 
lacZ. eGFP+ EPDCs were cultured on the outside of the barrier for 2 hours before the 
barrier was removed. After the barrier was removed, the eGFP+ cells were given 72 hours 
to migrate. Images were then taken under a confocal microscope (LSM 510 Meta, Zeiss, 
Germany). In order to obtain a complete view, a tiled scan was performed to piece 
together 16 images at 40x into a unified image. 
2.3.8 General Tissue Processing 
Neonatal NOS3+/+, NOS3+/-, NOS3-/-, NOS3Tg/NOS3-/- and NOS3Tg mice were used 
for analysis. Neonatal hearts and lungs were isolated and fixed in 4% paraformaldehyde, 
dehydrated, and embedded in paraffin. Five micro-meter transverse serial sections were 
mounted onto albumin/glycerin coated glass slides.  
2.3.9 Real Time RT-PCR 
Total RNA was isolated from cultured fetal hearts with a RNA isolation kit 
(Qiagen, Canada). cDNA was synthesized using M-MLV (Invitrogen, Canada) reverse 
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transcriptase and random primers (Invitrogen, Canada). Real-time PCR was conducted 
using SYBR Green PCR Master Mix as per manufacturer's instructions (Eurogentec, 
USA). The oligonucleotide primers used in this study are summarized in Supplementary 
Table 1. Samples were amplified for 35 cycles using MJ Research Opticon Real-Time 
PCR machine. The expression levels of Gata4, VEGFa, FGF, EPO, and Wt1 in relation 
to 28S rRNA as a loading control were obtained. 
2.3.10 Immunohistochemistry and Immunofluorescence 
After deparaffination and rehydration of the slides, microwave antigen retrieval 
was applied by heating them for 10 min at 98°C in a citric acid buffer (0.01 M in aqua-
dest, pH 6.0). Inhibition of endogenous peroxidase was performed with a solution of 0.3% 
H2O2 in phosphate buffered saline (PBS) for 30 min. The slides were incubated overnight 
with either 1:500 anti-troponin I (Santa Cruz Biotechnology, USA), 1:3,000 anti-α-
smooth muscle actin (Sigma- Aldrich, USA), 1:500, 1:300 anti-Wt1 (Calbiochem, USA) 
or 1:1000 anti-NOS3 (BD Transduction Laboratories, USA). Next, the secondary 
antibodies was added for 60 min with either 1:200 horse anti-mouse biotin (Vector  
Laboratories, USA) or 1:200 goat anti-rabbit biotin (Vector  Laboratories, USA) in PBS. 
Subsequently, slides were incubated with ABC reagent (Vector Laboratories, USA) for 
30 min. For visualization, the slides were incubated with 400 μg/ml 3-3’di-
aminobenzidin tetrahydrochloride (Sigma-Aldrich Chemie, USA) and 100 μL of 30% 
H2O2 dissolved in PBS for 10-15 min. Counterstaining was performed with 0.1% 
hematoxylin (Merck, Germany). For immunofluorescence staining, following primary 
antibody incubation, 1:500 goat anti-rabbit fluorescent secondary antibody (Jackson 
ImmunoResearch, USA) was used. Nuclei were stained with 1:50000 Hoechst 33342 
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(Invitrogen, Canada). Cardiomyocyte membranes were stained with 1:300 WGA (Vector 
Laboratories, USA).  
2.3.11  Western Blot Analysis 
Forty micrograms of protein lysates were subjected to separation on a 12% SDS-
PAGE gel, followed by electrotransfer to nitrocellulose membranes. Blots were probed 
with specific antibodies against NOS3 (BD Biosciences, USA) and GAPDH (Santa Cruz 
Biotechnology, USA), respectively. Signals were detected by the chemiluminescence 
detection method. 
2.3.12 Heart Function Measurements 
Left ventricular (LV) ejection fraction and fractional shortening were measured 
using Vevo 2100 (Visual Sonics, Canada). Briefly, 2-dimensional images of the heart 
were obtained in short-axis view using a dynamically focused 40 MHz probe. The M-
mode cursor was positioned perpendicular to the LV anterior and posterior walls. The LV 
internal end-diastolic dimension (LVIDd) and LV internal systolic dimension (LVIDs) 
were measured from M-mode recordings. LV ejection fraction was calculated as: EF (%) 
= [(LVIDd)3 - (LVIDs)3]/(LVIDd)3×100. Fractional shortening was calculated as: FS (%) 
= (LVIDd-LVIDs)/LVIDd×100. The M-mode measurements of the left ventricular 
ejection fraction and fractional shortening were averaged from 3 cycles.  
2.3.13 EPDC Outgrowth 
E12.5 NOS3+/+ and NOS3-/- hearts were planted on a 35 mm petri dish for 3 days 
to allow outgrowth of epicardial cells, which are epicardial-derived cells (EPDCs). After 
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3 days, these hearts were imaged under phase contrast (Observer D1, Zeiss, Germany). 
Their maximum migration distance was measured. 
2.3.14 Statistical Analysis 
Data are presented as mean±SEM. Survival curves were created by the method of 
Kaplan and Meier and compared by log-rank test. Unpaired Student’s t test was used for 
2 group comparisons. One way ANOVA followed by Student-Newman-Keuls test was 
performed for multi-group comparisons. Two way ANOVA test was performed for multi-
group, multi-treatment comparisons. A two-sided P<0.05 was considered statistically 
significant. All statistical analyses were performed using GraphPad Prism software 3.0. 
 
2.4 RESULTS 
2.4.1 Characterization of NOS3TG and NOS3TG;NOS3-/- mice.  
In order to study the specific role of NOS3 in coronary artery development, a 
cardiac-specific NOS3 transgenic mouse (NOS3Tg) was generated under the control of -
myosin heavy chain promoter.17 Expression of human NOS3 was detected only during 
embryonic development and specifically in the heart of NOS3Tg mice (Figure 2.1A-D). 
The NOS3Tg mice were then crossed with NOS3-/- to create the NOS3Tg;NOS3-/- mouse, an 
animal that lacks NOS3 in all organs except the heart during embryogenesis (Figure 2.1B, 
D). Since the gaseous molecule NO can freely diffuse between cells, NOS3 
overexpression in cardiomyocytes rescued NOS3 expression in NOS3-/- hearts.  
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Figure 2.1 Generation of mice with cardiomyocyte specific overexpression of human 
nitric oxide synthase-3 (hu-NOS3) during embryonic development. (A) Construct used 
for the generation of mice with cardiomyocyte specific overexpression of hu-NOS3 under 
the control of -myosin heavy chain (MHC). (B) NOS3 protein levels in the heart at 
E12.5, P0 and 5 months of age by Western blot analysis. Tg;-/- and Tg;+/+ indicate 
NOS3Tg;NOS3-/- and NOS3Tg, respectively. (C) Expression of the hu-NOS3 transgene was 
restricted in the heart at P0. Hu-NOS3 mRNA was analyzed by RT-PCR. (D) Western 
blot analysis showed decreased NOS3 expression from NOS3+/+ to NOS3+/- to NOS3-/- 
animals.  (E) NOS3 immunostaining at E12.5 showing expression of the Hu-NOS3 
transgene. Endogenous NOS3 expression was mostly located in the endocardium and 
capillary endothelium in the NOS3+/+ mice.  NOS3-/- mice showed no detectable 
expression of NOS3. NOS3Tg;NOS3-/- mice showed strong NOS3 expression in the 
myocardium, but not in the endocardium or capillary endothelium. NOS3Tg mice showed 
strong NOS3 expression in the myocardium (transgene), endocardium and capillary 
endothelium (endogenous). Scale bar = 30 μm.    
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2.4.2 Deficiency in NOS3 results in spontaneous myocardial infarction.  
Deficiency in NOS3 resulted in 73% mortality within the first 4 days after birth 
(Figure 2.2E). Coronary artery malformation may lead to myocardial ischemia and cell 
death, resulting in myocardial infarction. To assess if myocardial infarction was the cause 
of death, P0 hearts were subjected to triphenyltetrazolium chloride (TTC), troponin I and 
hematoxylin/eosin (H/E) staining. TTC staining showed that NOS3-/- mice had a large 
area of tissue death near the apex of the heart (Figure 2.2A). Troponin I is a part of the 
troponin complex that is integral to muscle contraction and decreased levels of troponin I 
represent cardiomyocyte death.18 Our data showed troponin I immunostaining was 
decreased in the area of infarct in NOS3-/- mice (Figure 2.2A). H/E staining showed 
typical wavy fibers near the border of the infarct area with disappearance of nuclei and 
intense eosinophilic cytoplasm (Figure 2.2A), which are signs of acute myocardial 
infarction.19 ECG monitoring showed ST elevation and QRS inversion in neonatal NOS3-
/- mice, indicating myocardial ischemia and possible cardiac hypertrophy, respectively 
(Figure 2.2A). Spontaneous myocardial infarction was seen in 8/15 (53%) NOS3-/- 
animals at P0 (Figure 2.2B).  Consequently, left ventricular ejection fraction and 
fractional shortening were significantly decreased in the NOS3-/- compared to NOS3+/+ 
mice (P<0.05, Figure 2.2C-D). These abnormalities in NOS3-/- mice including myocardial 
infarction, cardiac dysfunction, and postnatal mortality were all rescued by cardiac-
specific overexpression of NOS3 (NOS3Tg;NOS3-/- mice, Figure 2.2A-E). 
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Figure 2.2 Myocardial infarction and postnatal survival in NOS3-/- mice. (A) Evidence of 
spontaneous myocardial infarction in NOS3-/- mice at P0. TTC staining shows a large 
area of tissue death near the apex of the heart. The images are adjacent cross sections of 
the heart near the apex. Troponin I staining shows a significant loss of troponin I in the 
infarct myocardium. H/E staining shows waviness of fibers near the border of the 
myocardium with intense eosinophilic cytoplasm. ECG tracing shows significant ST 
elevation (Arrows) and QRS inversion (Arrowheads), representing signs of myocardial 
ischemia and possible cardiac hypertrophy, respectively. White bar: 1mm. Black bar: 
40µm. (B) Spontaneous myocardial infarction in NOS3-/- animals at P0.  * P<0.01 vs. 
NOS3+/+, NOS3Tg;NOS3-/- and NOS3Tg mice. Tg;-/- and Tg;+/+ indicate NOS3Tg;NOS3-/- 
and NOS3Tg, respectively. (C-D) Heart function assessed by echocardiography in 
NOS3+/+, NOS3-/-, NOS3Tg;NOS3-/- and NOS3Tg mice at P0. N=5-6 mice per group. * 
P<0.01 vs. NOS3+/+ mice. † P <0.01 vs. NOS3-/-. (E) Thirty-day survival after birth in 
NOS3+/+, NOS3-/-, NOS3Tg;NOS3-/- and NOS3Tg mice. * P<0.001 vs. NOS3+/+, 
NOS3Tg;NOS3-/- and NOS3Tg mice. 
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2.4.3 Deficiency in NOS3 impairs coronary artery development. 
NOS3-/- and NOS3+/- hearts at P0 showed less branching and significant decreases 
in the left and right coronary artery diameters (Figure 2.3A-D). Three-dimensional 
reconstructions of the heart showed a significant decrease in coronary volume in NOS3-/- 
mice (P<0.01, Figure 2.3E, Figure 2.4A ). Cardiomyocyte-specific NOS3 overexpression 
completely rescued these defects in the NOS3-/- mice (Figure 2.3A-E, Figure 2.4A).  
Since a decrease in coronary artery volume may have been a result of a smaller 
myocardial mass, myocardial volume and thickness were analyzed. However, both 
myocardial volume and thickness were increased in NOS3-/- and NOS3+/- compared to 
NOS3+/+ mice (P<0.01, Figure 2.4B-C). In order to determine if the increased myocardial 
volume and thickness are a result of cardiac hypertrophy, cardiomyocyte cell size and 
nuclear size of P0 hearts were measured. Cardiomyocyte cell and nuclear size was 
progressively increased in NOS3-/- and NOS3+/- compared to NOS3+/+ mice (P<0.01, 
Figure 2.4D-E). Therefore, our data showed an increased myocardial mass accompanied 
by severe coronary artery hypoplasia. These defects NOS3-/- mice were completely 
rescued by cardiomyocyte-specific NOS3 overexpression (P<0.01, Figure 2.4B-E).   
The coronary artery network is established by E15.5 in mice.11 To assess the onset 
of the coronary artery malformations, we further analyzed coronary artery development at 
E15.5. Coronary artery abundance, vessel diameter and volume were all significantly 
decreased while myocardial thickness was increased in NOS3-/- compared to NOS3+/- and 
NOS3+/+ mice at E15.5 (P<0.01, Figure 2.5A-F). These results suggest that the onset of 
the defect is prior to E15.5. Consistent with our P0 data, these defects were completely 
rescued by cardiomyocyte-specific NOS3 overexpression (P<0.01, Figure 2.5A-F). Since 
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coronary artery formation at E15.5 was not impaired in NOS3+/- mice, all subsequent 
molecular analyses on early coronary artery development were carried out in NOS3-/- in 
comparison with NOS3+/+  mice. 
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Figure 2.3 Immunohistochemical analysis of coronary artery development at P0. (A) 
Heart sections were stained with vascular smooth muscle α-actin to identify coronary 
arteries. Coronary arteries were smaller and less abundant in NOS3-/- and NOS3+/- 
compared to NOS3+/+ mice. Cardiac specific overexpression of NOS3 (NOS3Tg;NOS3-/-) 
restored coronary abundance in NOS3-/- mice. Coronary arteries are indicated by red 
arrows. Scale bar = 60 μm. (B-D) Left and right coronary artery diameter and abundance 
measured at 50 µm from the aortic orifice were significantly decreased NOS3-/- and 
NOS3+/- compared to NOS3+/+ mice, which was restored in NOS3Tg;NOS3-/- mice. N=5 
hearts per group.* P<0.01 vs. NOS3+/+, † P <0.01 vs. NOS3+/-.  ‡ P <0.01 vs. NOS3-/-. 
Tg;-/- and Tg;+/+ indicate NOS3Tg;NOS3-/- and NOS3Tg, respectively. (E) Coronary 
artery volume was significantly decreased NOS3-/- and NOS3+/- compared to NOS3+/+ 
mice, which was restored in NOS3Tg;NOS3-/- mice. N=5 hearts per group. * P<0.01 vs. 
NOS3+/+. † P <0.01 vs. NOS3-/-.  
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Figure 2.4 3D reconstruction of coronary artery development at P0. (A) Coronary 
arteries shown in green were less abundant in NOS3-/- and NOS3+/- compared to NOS3+/+ 
mice.  Cardiac specific overexpression of NOS3 restored coronary artery abundance in 
NOS3-/- mice. Atria were excluded from the reconstruction in order to view the origins of 
the coronary arteries. (B-C) Ventricular wall thickness and myocardial volume were 
significantly increased in NOS3-/- and NOS3+/- compared to NOS3+/+ mice. Cardiac 
overexpression of NOS3 (NOS3Tg;NOS3-/-) restored myocardial thickness and volume to 
similar levels as in the NOS3+/+ mice. (D-E) Cross-section cardiomyocyte cell and 
nucleus size was significantly increased NOS3-/- and NOS3+/- compared to NOS3+/+ mice. 
Cardiac overexpression of NOS3 (NOS3Tg;NOS3-/-) restored myocardial thickness to 
similar levels as in the NOS3+/+ mice. N=4 hearts per group. *P<0.01 vs. NOS3+/+mice, 
†P<0.01 vs. NOS3+/- mice, ‡P <0.01 vs. NOS3-/-. Tg;-/- and Tg;+/+ indicate 
NOS3Tg;NOS3-/- and NOS3Tg, respectively. 
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Figure 2.5 Coronary artery development at E15.5. (A) 3D reconstruction of E15.5 hearts. 
Coronary arteries shown in green were less abundant in NOS3-/- compared to NOS3+/- and 
NOS3+/+ mice.  Cardiac specific overexpression of NOS3 restored coronary artery 
abundance in NOS3-/- mice. Atria were excluded from the reconstruction in order to view 
the origins of the coronary arteries. (B-E) Coronary artery vessel diameter, abundance 
and volume were significantly decreased in NOS3-/- mice compared to NOS3+/- and 
NOS3+/+, which were restored in NOS3Tg;NOS3-/- mice. N=5 hearts per group. Tg;-/- and 
Tg;+/+ indicate NOS3Tg;NOS3-/- and NOS3Tg, respectively. (F) Ventricular wall thickness 
was significantly increased in NOS3-/- compared to NOS3+/- and NOS3+/+ mice. 
Cardiomyocyte specific overexpression of NOS3 (NOS3Tg;NOS3-/-) restored myocardial 
thickness to similar levels as in the NOS3+/+ mice. N=4 hearts per group. For B-F, 
*P<0.01 vs. NOS3+/+ mice, † P<0.01 vs. NOS3-/-. 
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2.4.4 Down-regulation of transcription and growth factors in E12.5 NOS3-/- hearts. 
Capillary networks in the embryonic heart begin to develop at E12.5, and are 
regulated by transcription and growth factors that are critical to heart morphogenesis and 
coronary artery formation.11 Our data showed that the mRNA levels of Gata4, VEGFa, 
FGF and EPO were significantly decreased in the NOS3-/- compared with NOS3+/+ hearts, 
and were completely restored in the NOS3Tg;NOS3-/- hearts (P<0.05, Figure 2.6A-D). 
Treatment with ODQ, a soluble guanylyl cyclase inhibitor significantly decreased Gata4 
and Wt1 mRNA expression in the NOS3+/+ hearts (P<0.05, Figure 2.6E-F). Conversely, 
NOS3-/- hearts treated with 8-Bromo-cGMP, a cGMP analog showed a significant 
increase in Gata4 and Wt1 mRNA levels (P<0.05, Figure 2.6G-H). These data suggest 
that NOS3 regulates the expression of Gata4 and Wt1 through a cGMP-dependent 
signaling pathway. 
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Figure 2.6 Myocardial mRNA expression of transcription and growth factors. (A-D) 
E12.5 hearts were collected and mRNA levels of Gata4, VEGFa, FGF and EPO were 
analyzed by real-time RT-PCR. The mRNA levels of Gata4, VEGFa, FGF and EPO were 
significantly decreased in NOS3-/- compared with NOS3+/+ mice, which were restored by 
cardiac specific NOS3 overexpression in the NOS3Tg;NOS3-/- hearts. N=6-7 per group. * 
P<0.01 vs. NOS3+/+ mice.  † P <0.01 vs. NOS3-/- mice. Tg;-/- and Tg;+/+ indicate 
NOS3Tg;NOS3-/- and NOS3Tg, respectively. 
(E-H) E12.5 ex vivo heart cultures were used to investigate NOS3 signaling. Cultured 
NOS3+/+ and NOS3-/- hearts were treated with 100 µM ODQ, a soluble guanylate cyclase 
inhibitor, or 2 mM 8-Br-cGMP, a cGMP analog, for 6 hrs. ODQ decreased Gata4 and 
Wt1 mRNA levels in NOS3+/+ hearts while 8-Br-cGMP restored Gata4 and Wt1 mRNA 
levels in NOS3-/- hearts. N=3-4 heart cultures per group. * P<0.05 vs. controls.  
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2.4.5 Deficiency in NOS3 decreases epicardium-derived cells (EPDCs) migration. 
EPDCs express Wt1 and their migration into the myocardium is essential to the 
formation of coronary arteries.13, 20 The number of Wt1+ epicardial cells was significantly 
decreased in NOS3-/- compared to NOS3+/+ hearts at E12.5 (P<0.01, Figure 2.7A-B). In 
addition, myocardial Wt1 mRNA levels were also significantly decreased in NOS3-/- 
compared with NOS3+/+ mice (P<0.01, Figure 2.7C). Decreased myocardial expression of 
Wt1 and number of Wt1+ epicardial cells were rescued in NOS3Tg;NOS3-/- mice (P<0.01, 
Figure 2.7A-C). To study the role of NOS3 in EPDCs migration, a co-culture system was 
employed (Figure 2.8A). EPDCs were isolated from E13 embryos overexpressing 
enhanced green fluorescence protein (eGFP). The cultured EPDCs were typical cobble 
stone shape and 100% positive for epicardin and Wt1. Cardiomyocytes was verified by α-
actinin staining (Figure 2.8B). eGFP+ EPDCs were then co-cultured with either E13 
NOS3+/+ or NOS3-/- cardiomyocytes treated with adenoviral lacZ or adenoviral NOS3 for 
72 hours. Our data showed migration of eGFP+ EPDCs was significantly decreased 
towards the NOS3-/- compared to the NOS3+/+ cardiomyocytes (Figure 2.8C-D). However, 
EPDC migration was increased in cardiomyocytes treated with adenoviral NOS3 
compared to adenoviral lacZ controls (Figure 2.8C-D). Finally, to assess EPDC migration 
and proliferation in the developing heart, ex vivo heart explants were employed. Our data 
showed ex vivo EPDC migration and proliferation were significantly decreased in the 
NOS3-/- compared with NOS3+/+ hearts (P<0.01, Figure 2.8E-F). 
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Figure 2.7 Characterization and quantification of Wt1+ epicardial progenitor cells. (A) 
E12.5 hearts were immunostained for Wt1 and representative images from NOS3+/+, 
NOS3-/- , NOS3Tg;NOS3-/- and NOS3Tg hearts are shown. The majority of Wt1+ cells are in 
the epicardium with limited expression in the myocardium. Scale bar = 60 μm. (B) 
Quantitative analysis showed a significant reduction in Wt1+ epicardial cells in NOS3-/- 
compared with NOS3+/+ hearts, which was restored by cardiac specific NOS3 
overexpression in the NOS3Tg;NOS3-/- hearts. N=4-5.  
(C) Wt1 mRNA levels were analyzed in E12.5 hearts by real time RT-PCR. Wt1 mRNA 
expression was significantly decreased in the NOS3-/- compared with NOS3+/+ hearts, 
which was restored in NOS3Tg;NOS3-/- hearts. N=6-7 per group. For B and C, *P<0.01 vs. 
NOS3+/+ mice,  † P<0.01 vs. NOS3-/-. Tg;-/- and Tg;+/+ indicate NOS3Tg;NOS3-/- and 
NOS3Tg, respectively. 
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Figure 2.8 Migration of epicardium-derived cells (EPDCs). (A) EPDCs were isolated 
from E13 hearts and co-cultured with cardiomyocytes as shown. The number of EPDCs 
migrated towards the cardiomyocytes was determined. (B) A representative confocal tiled 
image of the EPDCs and cardiomyocyte co-culture. EPDCs (green) and cardiomyocytes 
were isolated from eGFP transgenic and C57BL6 wild-type mice, respectively. 
Cardiomyocytes were stained with cardiac -actinin (red). (C) Quantitative analysis from 
(D) shows that EPDC migration was significantly decreased in NOS3-/- compared to 
NOS3+/+ cardiomyocyte co-cultures, which was restored by adenoviral NOS3 treatment. 
N=3-5 per group. *P<0.01 vs. NOS3+/+ mice. †P<0.01 vs. respective Ad-lacZ treated 
groups. (D) NOS3 expression in cardiomyocytes promoted EPDCs migration. 
Representative confocal tiled images of eGFP+ EPDCs co-cultured with NOS3+/+ and 
NOS3-/- cardiomyocytes, which were treated lacZ or NOS3 adenoviral constructs.  
(E) Representative images of EPDC outgrowth of E12.5 NOS3+/+ and NOS3-/- hearts. 
Scale bar = 250 μm. (F) Quantitative analysis shows that maximum EPDC migration 
distance was significantly decreased in NOS3-/- hearts compared with NOS3+/+ hearts. 
N=7-8, *P<0.01 vs. NOS3+/+ heart. (G) Proposed signaling pathway of NOS3 on 
coronary artery development. NOS3 promotes the expression of Gata4 and Wt1 via 
cGMP-dependent mechanisms. The production of growth factors (VEGFa, FGF and EPO) 
by Gata4 and EPDCs migration by Wt1 contribute to the critical role of NOS3 on 
coronary artery development. Dash lines represent signalling pathways shown by others. 
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2.5 DISCUSSION 
Growing evidence suggests that NO plays an important role in embryonic heart 
development. To this end, we and others have previously shown that lack of NOS3 
results in congenital septal defects and bicuspid aortic valves in mice.21-24 In addition, 
impaired capillary and microvessel development has been shown in the heart and lungs of 
NOS3-/- mice, respectively.16, 25 The present study was carried out to further examine the 
role of NOS3 in coronary artery development. We demonstrated for the first time that 
deficiency of NOS3 leads to hypoplastic coronary arteries. These results show that NOS3 
plays a critical role in normal coronary artery development (Figure 2.8G). To rescue the 
coronary phenotype in the NOS3-/- mice, we generated a mouse with cardiomyocyte-
specific overexpression of NOS3 during embryonic development. The NOS3Tg mice had 
a normal cardiac and coronary artery phenotype. Importantly, cardiomyocyte-specific 
overexpression of NOS3 completely rescued the abnormal coronary artery development, 
cardiac hypertrophy and postnatal survival in the NOS3-/- mice. The data strongly suggest 
that normal coronary artery development is driven by local NO signaling from 
endothelial cells and/or cardiomyocytes within the developing heart.  
Our data showed that deficiency in NOS3 down-regulated the expression of Gata4, 
VEGFa, FGF and EPO in the embryonic heart. Additionally, Wt1, a transcription factor 
critical for EMT and coronary artery formation, was also down-regulated and the number 
of EPDCs was decreased in the NOS3-/- hearts. Furthermore, lack of NOS3 decreased 
EPDCs migration towards the cardiomyocytes. Flow dependent dilation and remodeling 
are important mechanisms in the regeneration of adult blood vessels.11, 15 However, 
initiation of embryonic coronary artery development relies more on de novo arterial 
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plexuses formation that are independent of blood flow. Eventually at around E14.5, 
arterial plexuses are connected and the connection of coronary artery to the aorta is made. 
After this point, flow dependent dilation and remodeling in the coronary artery are 
important in establishing further expansion of the vessels similar to adult blood vessel 
generation.11, 15 This process, however, is not NOS3 dependent.26 Our results show that 
NOS3 promotes normal coronary artery development via increases in expression of 
transcription and growth factors, and EPDCs migration into the myocardium (see Figure 
2.8G).   
NOS3-/- mice have a high rate of postnatal mortality. We have previously shown 
that within 10 days after birth, mortality was 85%, 38% and 13% for NOS3-/-, NOS3+/- 
and WT mice, respectively.21 Most animals died within the first 3 days after birth. 
Consistent with our finding, Han et al. showed that 40% of NOS3-/- offspring succumbed 
within the first hour of birth.25 However, they did not monitor their animal survival 
beyond one hour of birth. In the present study, the mortality of NOS3-/- mice was 73% in 
the first 4 days after birth, which is in agreement with the previous studies.21, 25 
Additionally, we demonstrated a dose-dependent cardiac dysfunction at P1 with the loss 
of one or both NOS3 alleles.21 Interestingly, this gene dose-dependent response was also 
observed in the coronary artery formation of NOS3-/-, NOS3+/- and NOS3+/+ mice at P0 in 
the present study. These data suggest that hypoplastic coronary arteries may contribute at 
least in part to postnatal cardiac dysfunction and mortality in NOS3-/- mice.  
Hypoplastic coronary artery disease (HCAD) is often associated with myocardial 
infarction and sudden cardiac death when the heart is stressed.7 In the present study, 
coronary artery malformation is accompanied by spontaneous myocardial infarction in 
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postnatal NOS3-/- mice. Our study demonstrated that NOS3 deficiency results in 
hypoplastic coronary arteries, a condition that mirrors HCAD in humans. Interestingly, 
recent studies have shown that a common 894G>T single nucleotide polymorphism, 
which reduces NOS3 activity, is associated with up to 2.3 fold increased risk of 
congenital heart disease, especially conotruncal heart defects.27 In addition, 
environmental factors and maternal conditions including psychological stress, 
hypertension and diabetes, which decrease NOS3 expression and/or activity, are 
associated with increased risks of congenital heart disease.28-30 Thus, it is possible that 
decreased NOS3 signaling may promote the development of congenital heart disease in 
patients with these environmental and maternal conditions. Although further studies are 
required to analyze NOS3 gene mutation in patients with HCAD, the present study 
suggests NOS3 is critical to coronary artery development and deficiency or mutation of 
NOS3 gene may lead to HCAD.  Our study is the first to implicate NOS3 deficiency in 
the pathogenesis of HCAD and may help to design strategies in the diagnosis, prevention 
and treatment of HCAD in humans.  
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3 CHAPTER 3 
Nitric Oxide Synthase-3 Promotes Embryonic Development of Atrioventricular 
Valves 
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3.1 CHAPTER SUMMARY 
Aims: Nitric oxide synthase-3 (NOS3) has recently been shown to promote endothelial-
to-mesenchymal transition (EndMT) in the developing atrioventricular (AV) canal. The 
present study was aimed to investigate the role of NOS3 in embryonic development of 
AV valves. We hypothesized that NOS3 promotes embryonic development of AV valves 
via EndMT.  
Methods and Results: To test this hypothesis, morphological and functional analysis of 
AV valves were performed in wild-type (WT) and NOS3-/- mice at postnatal day 0. Our 
data show that the overall size and length of mitral and tricuspid valves were decreased in 
NOS3-/- compared with WT mice. Echocardiographic assessment showed significant 
regurgitation of mitral and tricuspid valves during systole in NOS3-/- mice. These 
phenotypes were all rescued by cardiac specific NOS3 overexpression. To assess EndMT, 
immunostaining of Snail1 was performed in the embryonic heart. Snail1 positive and 
total mesenchymal cells in the AV cushion were decreased in NOS3-/- compared with WT 
mice at E10.5 and E12.5, which was completely restored by cardiac specific NOS3 
overexpression. In cultured embryonic hearts, NOS3 promoted transforming growth 
factor (TGFβ), bone morphogenetic protein (BMP2) and Snail1expression through cGMP. 
Furthermore, mesenchymal cell formation and migration from cultured AV cushion 
explants were decreased in the NOS3-/- compared with WT mice.  
Conclusion: NOS3 promotes AV valve formation during embryonic heart development 
and deficiency in NOS3 results in AV valve insufficiency. 
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3.2 INTRODUCTION 
Valvular heart disease is a significant health problem and contributes to more than 
44,000 deaths in United States annually.1 The causes of valvular heart disease include 
congenital malformation and rheumatic disease which is secondary to bacterial infection. 
Congenital valve disease affects about 2% of the general population.2, 3 The disease may 
manifest as valvular stenosis, an obstruction of outflow, or as regurgitation, a defective 
closure resulting in backward flow. Congenital valve malformations tend to cluster in 
families among both close and distant relatives, suggesting a genetic component of this 
disease.4, 5 However, molecular mechanisms responsible for congenital valve disease are 
still not fully understood.  
Nitric oxide synthase (NOS) enzymes convert L-arginine to L-citrulline and 
produce nitric oxide (NO), a signaling molecule involved in a wide range of 
physiological processes including apoptosis, angiogenesis, cell proliferation and 
differentiation.6-8 Three distinct isoforms of NOS has been identified: neuronal NOS 
(NOS1), inducible NOS (NOS2) and endothelial NOS (NOS3). The expression of NOS3 
starts around E9.5 during early mouse embryonic heart development.9 This expression 
remains high until E13.5. By E14.5, the levels of NOS3 expression decrease in both atria 
and ventricles. After E19.5 low NOS3 levels are still detectable and this level of NOS3 
expression in the myocardium remains into adulthood.9 
The atrioventricular (AV) valve development starts at E9 with the formation of 
endocardial cushions. A subpopulation of endocardial cells of the endocardial cushion 
undergoes endothelial-to-mesenchymal transition (EndMT) and provides the primary cell 
source for the development of AV valves.10 Proliferation of the mesenchymal cells and 
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matrix deposition extend the cushions into the cardiac lumen and form primordia of each 
distinct valve. This is followed by elongation and remodeling of the valve primordia, 
which leads to the gradual formation of valves by E15.11 The valves continue to grow and 
remodel throughout heart development and well after birth.12-14 EndMT is a crucial 
process for proper formation of AV valves.15 Transforming growth factor (TGFβ), bone 
morphogenetic protein (BMP)-2, and Snail1 have been shown to promote EndMT and 
valve formation.16 We have shown that NOS3 is important for embryonic heart 
development.17 Deficiency in NOS3 leads to congenital septal defect, bicuspid aortic 
valves and coronary artery malformation.18-20 In addition, Notch-dependent NOS3 
activation has been shown to promote EndMT in the developing atrioventricular (AV) 
canal from E9 to E11.5 via activation of the PI3-kinase/Akt pathway.21 The temporal 
expression pattern of NOS3 peaks during AV valve formation along with its role in 
EndMT, suggesting that NOS3 may participate in the development of the AV valves. 
However, the role of NOS3 in the formation and functioning of AV valves has not been 
studied. In the present study, we hypothesized that NOS3 promotes embryonic 
development of AV valves via EndMT. To test this hypothesis, morphological changes 
and functional competence of AV valves were studied in wild-type (NOS3+/+), NOS3-/- 
and cardiac specific NOS3 overexpressing (NOS3Tg) mice. Furthermore, the role of 
NOS3 in endocardial EndMT and signaling pathway critical to AV valve development 
was also examined. Our study demonstrated that NOS3 promotes endocardial EndMT 
and embryonic AV valve development. 
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3.3 METHODS 
3.3.1 Animals 
Breeding pairs of NOS3-/- (stock No. 002684) and wild-type C57BL/6 (NOS3+/+) 
mice were purchased from Jackson Laboratory (Bar Harbor, Maine). A breeding program 
was carried out to produce neonates. Genotyping of NOS3-/- and NOS3+/+ mice was 
performed by a polymerase chain reaction (PCR) method using genomic DNA prepared 
from tail biopsies. A timed breeding program was carried out. Vaginal plugging was 
monitored in the morning of each day and when plugged, was considered 0.5 days into 
pregnancy. Embryonic hearts were collected at E10.5, E12.5, and postnatal day 0. The 
investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the National Institutes of Health (NIH Publication #85-23, revised 1996) 
and the experimental protocols were approved by Animal Use Subcommittee at Western 
University. 
3.3.2 Generation of Human NOS3 Transgenic Mice 
A new line of cardiac-specific mice overexpressing human isoforms of NOS3 
(NOS3Tg) was generated.20 Briefly, human NOS3 complementary DNA was inserted into 
the β-myosin heavy chain promoter expression vector 22 to permit the expression of 
human NOS3 only during embryonic development and specifically in the heart. Our 
previous studies have shown that the transgene is specifically expressed in the heart 
during embryonic development.20 Genotypes were identified by PCR using genomic 
DNA from tail biopsies. 
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3.3.3 General Tissue Processing 
Neonatal NOS3+/+,  NOS3-/-, NOS3Tg/NOS3-/- and NOS3Tg mice were used for 
analysis. Hearts were isolated and fixed in 4% paraformaldehyde, dehydrated, and 
embedded in paraffin. Five micro-meter transverse serial sections were mounted onto 
albumin/glycerin coated glass slides.  
3.3.4 Immunohistochemistry and Immunofluorescence 
Established protocols were used with minor modifications 18, 20, 23. Briefly, after 
deparaffination and rehydration of the slides, microwave antigen retrieval was applied by 
heating them for 10 min at 98°C in a citric acid buffer (0.01 M in aqua-dest, pH 6.0). 
Inhibition of endogenous peroxidase was performed with a solution of 0.3% H2O2 in 
phosphate buffered saline (PBS) for 30 min. The slides were incubated overnight with 
either 1:500 anti-Snail1 (Abcam, USA). Next, the goat anti-rabbit secondary antibody 
conjugated with biotin (1:200, Vector Laboratories, USA) was added for 60 min in PBS. 
Subsequently, slides were incubated with ABC reagent (Vector Laboratories, USA) for 
30 min. For visualization, the slides were incubated with 400 μg/ml 3-3’di-
aminobenzidin tetrahydrochloride (Sigma-Aldrich, USA) and 100 μL of 30% H2O2 
dissolved in PBS for 10-15 min. Counterstaining was performed with 0.1% hematoxylin. 
The size and length of AV valves were measured at the proximal (hinge) and distal 
aspects of the leaflets as described previously.24 
3.3.5 Three-Dimensional Reconstructions and Histological Analysis 
Three-dimensional (3D) reconstructions of the heart and AV valves were 
performed using Masson’s Trichrome stained serial sections of P1 hearts through the 
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AMIRA® software (Template Graphics Software, USA) as previously described 20. AV 
valve volumes were determined using the AMIRA® program. 
3.3.6 Heart Function Measurements 
Left ventricular (LV) and right ventricular ejection fraction and fractional 
shortening were measured using the Vevo 2100 ultrasound imaging system (Visual 
Sonics, Canada).20 Briefly, 2-dimensional images of the heart were obtained in short-axis 
view using a dynamically focused 40 MHz probe. The M-mode cursor was positioned 
perpendicular to the LV anterior and posterior walls. The LV internal end-diastolic 
dimension (LVIDd) and LV internal systolic dimension (LVIDs) were measured from M-
mode recordings. LV ejection fraction was calculated as: EF (%) = [(LVIDd)3 - 
(LVIDs)3]/(LVIDd)3×100. Fractional shortening was calculated as: FS (%) = (LVIDd-
LVIDs)/LVIDd×100. The M-mode measurements of the left ventricular ejection fraction 
and fractional shortening were averaged from 3 cycles. Both left and right atrial areas 
were traced and calculated under the apical 4-chamber view in B-mode. AV valve E/A 
ratio, regurgitation and flow pattern were measured through both color flow Doppler 
recordings and pulsed-wave Doppler echocardiograms.25  
3.3.7 Ex vivo Heart Cultures 
E12.5 WT and NOS3-/- hearts were explanted and cultured in M199 medium 
(Sigma-Aldrich, USA) supplemented with 10% FBS as previous described.20 Hearts were 
stabilized for 2 hours prior to any treatment. Both WT and NOS3-/- hearts were beating 
throughout the entirety of the experiment. WT and NOS3-/- hearts were treated with 100 
µM 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ) (Sigma-Aldrich, USA) and 2 
mM 8-Bromo-cGMP (Sigma-Aldrich, USA), respectively for 6 hours. Some WT and 
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NOS3-/- hearts were treated with recombinant TGFβ protein (10 ng/ml) for 18 hours. 
Hearts were then collected and mRNA levels of Snail1, TGFβ and BMP2 were analyzed 
by real time RT-PCR. 
3.3.8 Real-time RT-PCR 
Standard protocol was used as previous described.7, 18, 20, 23 Briefly, total RNA was 
isolated from cultured fetal hearts with a RNA isolation kit (Qiagen, Canada). cDNA was 
synthesized using M-MLV (Invitrogen, Canada) reverse transcriptase and random 
primers (Invitrogen, Canada). Real-time PCR was conducted using SYBR Green PCR 
Master Mix as per manufacturer's instructions (Eurogentec, USA). The oligonucleotide 
primers used in this study are summarized in Online Supplementary Table 1. Samples 
were amplified for 35 cycles using Eppendorf Real-Time PCR machine and analyzed 
using cycle threshold (Ct) analysis. A ratio of target gene versus 28S rRNA was used to 
determine the relative expression of Snail1, BMP2 and TGFβ.23 
3.3.9 Measurement of cGMP 
The cGMP levels in the heart were measured using an ELISA kit according to the 
manufacturer’s instructions (ADI-900-014, Enzo Life Sciences, USA).26 Neonatal 
NOS3+/+, NOS3-/-, NOS3Tg/NOS3-/- and NOS3Tg hearts were used for analysis. Briefly, 10 
µg of protein lysates from the isolated hearts and standards were added to the cGMP 
conjugated to alkaline phosphatase and an anti-cGMP antibody, and incubated for 2 
hours at room temperature. This incubation allows the antibody to bind the cGMP in the 
sample or conjugate in a competitive manner. After 3 washes, p-nitrophenyl phosphate 
(pNpp) substrates were added and the plated and incubated for 1 hour at room 
temperature. This incubation allows the catalysis of pNpp substrate by the alkaline 
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phosphatase on the cGMP conjugate. The reaction was then stopped by tri-sodium 
phosphate solution and the optical density was read at 405 nm. The amount of signal is 
indirectly proportional to the amount of cGMP in the sample. 
3.3.10 Endocardial Cushion Explant Culture 
Endocardial cushion explants were cultured accordingly to methods previously 
described with minor modifications.27 Briefly, E10.5 NOS3+/+ and NOS3-/- hearts were 
planted on a 35 mm petri dish coated with 1 mg/ml collagen type I gel overnight for 
attachment. After attachment, the hearts were treated with 100 µl of M199 supplemented 
with 10% FBS and allowed 2 days for EndMT to occur. After 2 days, these hearts were 
imaged under phase contrast microscopy (Observer D1, Zeiss, Germany). The number of 
spindle-like mesenchymal cells was counted. 
3.3.11 Statistical Analysis 
Data are presented as mean ± SEM. Survival curves were created by the method 
of Kaplan and Meier and compared by log-rank test. Unpaired Student’s t test was used 
for 2 group comparisons. One way ANOVA followed by Student-Newman-Keuls test 
was performed for multi-group comparisons. P<0.05 was considered statistically 
significant. 
3.4 Results 
3.4.1 Deficiency in NOS3 impairs AV valve formation 
Trichrome staining of mitral and tricuspid valves in NOS3+/+, NOS3-/-, NOS3Tg 
and NOS3Tg;NOS3-/- mice at P0 is shown in Figure 3.1A-J. In NOS3-/- hearts, AV valves 
were much smaller than those of other genotypes. The size of proximal (hinge) and distal 
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aspects of the valve leaflets was measured as illustrated in Figure 3.1M. Quantitative 
analysis of mitral and tricuspid valves show that the size (thickness) and length of the 
proximal and distal leaflets were significantly smaller in the NOS3-/- compared with 
NOS3+/+ hearts (P<0.05, Figure 3.1E-L, 3.2F, 3.3F). Cardiomyocyte-specific NOS3 
overexpression (NOS3Tg;NOS3-/-) completely rescued these defects in the NOS3-/- mice 
(P<0.05, Figure 3.1D- F, 3.1J-L, 3.2F, 3.3F).  To investigate whether the valvular defect 
in the NOS3-/- animals is due to premature maturation, cell density in the valves was 
measured.12-14 Our data showed that there was no significant difference in cell density in 
mitral and tricuspid valves among all groups at P0 (Figure 3.2G and 3.3G). Furthermore, 
the decrease in valve length was evident as early as E15.5 in both mitral and tricuspid 
valves (Figure 3.4A-B). These data supports a developmental defect rather than 
premature maturation of the AV valves in NOS3-/- mice.  
The volume of the mitral and tricuspid valves was determined through 3D 
reconstructions (Suppl. Figure 3.2A-E and 3.3A-E). The normal mitral valve of NOS3+/+ 
mice had 2 distinct leaflets. However, the overall volume of the mitral valve was 
significantly smaller in NOS3-/- compared with NOS3+/+ mice, which was restored by 
cardiomyocyte-specific NOS3 overexpression in the NOS3Tg;NOS3-/- mice (P<0.01, 
Figure 3.2A-E).  The tricuspid valve of NOS3+/+ mice had 3 distinct leaflets. Similar to 
the findings in the mitral valve, the overall volume of tricuspid valve was significantly 
decreased in NOS3-/- compared with NOS3+/+ mice, which was completely rescued by 
cardiomyocyte-specific NOS3 overexpression in the NOS3Tg;NOS3-/- mice  (P<0.01, 
Figure 3.3A-E).  
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Figure 3.1 Malformation of mitral and tricuspid valves in NOS3-/- mice, which are 
rescued by cardiomyocyte-specific NOS3 overexpression (NOS3Tg;NOS3-/-). 
Representative tissue sections with Masson’s Trichrome staining of mitral (A-D) and 
tricuspid (G-J) valves in WT, NOS3-/-, NOS3Tg and NOS3Tg;NOS3-/- mice at P0. (E and 
F) Quantification of mitral valve size. (K and L) Quantification of tricuspid valve size. 
Anterior and posterior leaflets represent the valve leaflet closer to the septum and 
ventricular free wall, respectively.  (M) Valve size was measured at the proximal (hinge) 
and distal aspects of the leaflets. White arrows represent proximal and distal 
measurements. Black arrow points to the hinge of the valve. Scale bar = 60 µm. Data are 
mean  SEM from 5-8 mice per group. *P<0.05 vs. WT (NOS3+/+), †P<0.05 vs. NOS3-/- 
mice.  
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Figure 3.2 Three-dimensional (3D) reconstructions of mitral valve of WT, NOS3-/-, 
NOS3Tg and NOS3Tg;NOS3-/- mice at P0 (A-D). 3D reconstructions were made by putting 
together images taken from approximately 100 serial heart sections at 5 µm using Amira 
software. Valve locations in the heart are shown. Whole heart images are frontal views of 
the heart. Isolated valve images are viewed from the left atrium into the left ventricle. E. 
Quantitative analysis of mitral valve volume. Data are mean  SEM from 5 mice per 
group. F. Quantification of mitral valve length in P0 hearts. G. Quantification of mitral 
valve cell density in P0 hearts. *P<0.01 vs. WT. †P<0.01 vs. NOS3-/- mice.  Tg;-/- and 
Tg;+/+ indicate NOSTg;NOS3-/- and NOS3Tg, respectively. 
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Figure 3.3 3D reconstructions of tricuspid valve of WT, NOS3-/-, NOS3Tg and 
NOS3Tg;NOS3-/- mice at P0 (A-D). 3D reconstructions were made by putting together 
images taken from approximately 100 serial heart sections at 5µm using Amira software. 
Valve locations in the heart are shown. Whole heart images are frontal views of the heart. 
Isolated valve images are viewed from the right atrium into the right ventricle. E. 
Quantitative analysis of tricuspid valve volume. F. Quantification of tricuspid valve 
length in P0 hearts. G. Quantification of tricuspid valve cell density in P0 hearts. Data are 
mean  SEM from 5 mice per group. *P<0.01 vs. WT. †P<0.01 vs. NOS3-/- mice. Tg;-/- 
and Tg;+/+ indicate NOSTg;NOS3-/- and NOS3Tg, respectively. 
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Figure 3.4 Mitral and tricuspid valve length measurements at E15.5. A. Length of 
anterior and posterior leaflets of the mitral valve.  B. Length of anterior and posterior 
leaflets of the tricuspid valve. Data are mean  SEM from 5 mice per group. *P<0.05 vs. 
WT. †P<0.05 vs. NOS3-/- mice. Tg;-/- and Tg;+/+ indicate NOS3Tg;NOS3-/- and NOS3Tg, 
respectively. 
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3.4.2 Regurgitation of AV valves in NOS3-/- mice 
In order to investigate the functional significance of AV malformation in NOS3-/- 
mice, echocardiographic imaging analysis was performed on NOS3+/+, NOS3-/-, NOS3Tg 
and NOS3Tg;NOS3-/- mice at P0 live animals. Color flow Doppler recordings showed 
backflow of mitral (Figure 3.5A) and tricuspid (Figure 3.6A) valves in NOS3-/- mice. 
Using pulsed-wave Doppler, the backflow velocity and duration were quantified. The 
velocity and duration of backflow in mitral (Figure 3.5C-D) and tricuspid valves (Figure 
3.6C-D) were significantly increased in NOS3-/- compared with NOS3+/+ mice (P<0.05). 
Cardiomyocyte-specific NOS3 overexpression completely rescued these abnormalities in 
the NOS3-/- animals (Figure 3.5A-D, 3.6A-D). 
AV valve regurgitation could potentially result in lowered cardiac function. To this end, 
ejection fraction and fractional shortening were determined. Our data showed that 
ejection fraction and fractional shortening of both left and right ventricles were 
significantly decreased in NOS3-/- compared with NOS3+/+ mice (P<0.05, Figure 3.7A-D). 
Cardiomyocyte-specific NOS3 overexpression in NOS3-/- mice restored ejection fraction 
and fractional shortening in both left and right ventricles to levels comparable to the 
NOS3+/+ mice. Additionally, we assessed the E/A ratio of the AV valves, which 
represents diastolic function or the ability of the blood to flow from the atria to the 
ventricles. E represents the passive filling of blood from atria to ventricles, whereas A 
represents the active contraction of the atria that pumps blood to the ventricles. Our 
results showed that no significant difference was observed between all groups in E/A 
ratios or the ability of the blood to flow from the atria to the ventricles (Figure 3.7E-F). 
Lastly, as a consequence of AV valve regurgitation, the size of atria would increase due 
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to the backward flow from the ventricles. As expected, the size of both left and right 
atrium was significantly increased in the NOS3-/- compared with NOS3+/+ mice, which 
was restored in NOS3Tg;NOS3-/- mice at P0 (P<0.05, Figure 3.7G-H). 
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Figure 3.5 Regurgitation of mitral valve in NOS3-/- mice at P0. Backflow of mitral valves 
was determined by color (A) and pulsed-wave (B) Doppler echocardiography. Backflow 
during systole is indicated by arrows. WT mice had no backflow in mitral valves. 
However, NOS3-/- mice showed significant mitral valve backflow. (C-D) Quantification 
of mitral valve regurgitation. Significant regurgitation was observed in NOS3-/- mice, 
which were rescued by cardiomyocyte-specific NOS3 overexpression. Data are mean  
SEM from 6-7 mice per group. *P<0.01 vs. all other groups. +/+, WT; -/-, knockout; Tg, 
transgenic. Tg;-/- and Tg;+/+ indicate NOSTg;NOS3-/- and NOS3Tg, respectively. 
 
  
109 
 
  
110 
 
Figure 3.6 Regurgitation of tricuspid valve in NOS3-/- mice at P0. Backflow of tricuspid 
valves was determined by color (A) and pulsed-wave (B) Doppler echocardiography. 
Backflow during systole is indicated by arrows. WT mice had minor backflow in 
tricuspid valves. However, NOS3-/- mice showed marked tricuspid valve backflow. (C-D) 
Quantification of tricuspid valve regurgitation. Significant regurgitation was observed in 
NOS3-/- mice, which were rescued by cardiomyocyte-specific NOS3 overexpression. Data 
are mean  SEM from 6-7 mice per group. *P<0.01 vs. WT (NOS3+/+), †P<0.01 vs. 
NOS3-/-. +/+, WT; -/-, knockout; Tg, transgenic. Tg;-/- and Tg;+/+ indicate NOSTg;NOS3-
/- and NOS3Tg, respectively.  
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Figure 3.7 Cardiac function determined using echocardiography at P0. (A-D) Both left 
and right ventricular ejection fraction and fractional shortening were significantly 
decreased in the NOS3-/- mice compared with WT controls, which were rescued by 
cardiomyocyte-specific NOS3 overexpression. (E-F) E/A ratio showed no significant 
difference between all groups. (G-H) Left and right atrial size was significantly increased 
in NOS3-/- mice compared with WT controls, which was rescued by cardiomyocyte-
specific NOS3 overexpression. Data are mean  SEM from 6-7 mice per group. *P<0.05 
vs. WT (NOS3+/+), †P<0.05 vs. NOS3-/-. +/+, WT; -/-, knockout; Tg, transgenic. Tg;-/- 
and Tg;+/+ indicate NOSTg;NOS3-/- and NOS3Tg, respectively. 
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3.4.3 Snail1+ and total mesenchymal cells are decreased in the endocardial cushion 
of NOS3-/- mice 
Snail1 is a zinc finger transcriptional repressor, which inhibits adhesion molecule 
E-cadherin expression and induces EndMT during embryonic development.28, 29 
Therefore, Snail1 is an excellent marker of mesenchymal cells in the AV cushion. To 
further elucidate the role of NOS3 in early AV valve formation, immunostaining of 
Snail1 was performed and Snail1+ mesenchymal cells were quantified at E10.5 and E12.5. 
Our data showed that while there were no significant changes in the overall size and 
volume of the AV endocardial cushion at E10.5 and E12.5 (Figure 3.8D, G), the number 
of Snail1 positive mesenchymal cells (brown staining in histology) and total number of 
mesenchymal cells within the endocardial cushion were significantly decreased in the 
NOS3-/- compared with NOS3+/+ hearts at E10.5 and E12.5 (P<0.05, Figure 3.8A-C, E, F). 
Since reduction of mesenchymal cells in NOS3-/- hearts was seen at both E10.5 and E12.5, 
the rest of the analysis was done in E12.5 hearts. Three-dimensional reconstruction of 
Snail1 expression (labeled in red) in the NOS3+/+ mice showed Snail1 completely covered 
the outer part of the endocardial cushion, which represents cells that are actively 
undergoing EndMT (Figure 3.8A). However, in the NOS3-/- mice, only limited parts of 
the endocardial cushion were Snail1 positive, indicating the EndMT process is impaired 
in the NOS3-/- mice. The number of Snail1 positive and total mesenchymal cells was 
completely restored by cardiac specific NOS3 overexpression (P<0.05, Figure 3.8A-C, E, 
F).  
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Figure 3.8 EndMT is impaired in the AV cushion of NOS3-/- hearts at E12.5. (A) 3D 
reconstructions (Left and middle columns, Red for Snail1+ cells; Grey for cushion) and 
representative Snail1 immunostaining (Right column, Brown staining indicates Snail1+ 
cells). Scale bar = 50 µm. (B) Quantification of Snail+ mesenchymal cell volume from 
3D reconstructed AV cushions. (C) Total number of mesenchymal cells from E12.5 
cushions was quantified. (D) Quantification of endocardial cushion size at E12.5 from 3D 
reconstructions. (E) Quantification of Snail1+ endocardial cushion mesenchymal cells at 
E10.5 from 3D reconstructions. (F) Quantification of total endocardial cushion 
mesenchymal cells at E10.5. (G) Quantification of endocardial cushion size at E10.5 
from 3D reconstructions. N= 3-4 mice per group. *P<0.05 vs. NOS3+/+ or WT control. 
†P<0.05 vs. NOS3-/- or NOS3-/- control.   
116 
 
3.4.4 cGMP signaling is decreased in NOS3-/- hearts 
cGMP, a downstream signaling molecule of NOS3, was significantly decreased in 
the NOS3-/- compared with NOS3+/+ hearts at P0 (P<0.05, Figure 3.9A). Cardiac specific 
NOS3 overexpression in NOS3-/- mice increased myocardial cGMP to similar levels of 
NOS3+/+ mice (Figure 3.9A). To elucidate the precise role of NOS3 in regulating Snail1 
expression, ex vivo E12.5 heart cultures were employed. The TGFβ and BMP family 
proteins are critical to AV valve development.15, 16 Treatment with ODQ, a soluble 
guanylyl cyclase inhibitor significantly decreased TGFβ1, BMP2 and Snail1 mRNA 
expression in the WT hearts (P<0.05, Figure 3.9B-D). Conversely, NOS3-/- hearts treated 
with 8-Bromo-cGMP, a cGMP analog showed a significant increase in TGFβ1, BMP2 
and Snail1 mRNA levels (P<0.05, Figure 3.9B-D). These data suggest that NOS3 
regulates the expression of TGFβ1, BMP2 and Snail1 through a cGMP-dependent 
pathway. To investigate if TGFβ regulates Snail1 signalling, recombinant TGFβ is used 
to treat WT and NOS3-/- hearts. Our data showed that recombinant TGFβ protein 
treatment significantly increased Snail1 expression in both WT and NOS3-/- hearts 
(P<0.05, Figure 3.9E). 
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Figure 3.9 cGMP regulates expression of Snail1, TGF and BMP2 in E12.5 hearts. (A) 
cGMP levels in P0 hearts. (B-D) E12.5 ex vivo heart cultures. Cultured WT and NOS3-/- 
hearts were treated with ODQ (100 µM), a soluble guanylate cyclase inhibitor, or 8-Br-
cGMP (2 mM), a cGMP analog for 6 hrs. Snail1, TGF and BMP2 mRNA levels were 
determined by real-time RT-PCR. (E) E12.5 ex vivo heart cultures from WT and NOS3-/- 
mice were treated with recombinant TGFβ protein (10 ng/ml). TGF mRNA levels were 
determined by real-time RT-PCR. N=6 hearts per group for C-G. *P<0.05 vs. NOS3+/+ or 
WT control. †P<0.05 vs. NOS3-/- or NOS3-/- control.  
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3.4.5 EndMT is impaired in NOS3-/- endocardial cushions 
To further confirm the role of NOS3 in endocardial EndMT, endocardial cushions 
from E10.5 embryos were dissected and cultured on collagen type I gel. Collagen type I 
gel was chosen to simulate the in vivo conditions of the cardiac jelly, which the 
mesenchymal cells migrate into. After 2 days of culture, cells that underwent EndMT 
exhibited spindle-like morphology and migrated from the endocardial cushion into the 
collagen gel. Results showed the total number of mesenchymal cells was significantly 
decreased in NOS3-/- compared to NOS3+/+ explants (P<0.05, Figure 3.10A-B), 
suggesting NOS3 promotes endocardial EndMT.  
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Figure 3.10 Atrioventricular (AV) endocardial cushion explant culture from E10.5 
NOS3-/- and WT mice. (A) Spindle shaped mesenchymal cells (arrows) were formed after 
24 hours of culture. Lower panel is an enlargement of the boxed area. (B) The total 
number of mesenchymal cells per mm of explant cushion tissue was significantly 
decreased in NOS3-/- compared to WT explants. Data are mean  SEM from 6 explants 
per group. *P<0.05 vs. WT. Black scale bar = 100 µm, white scale bar = 10 µm. (C) 
Proposed signaling pathway by which NOS3 promotes endocardial EndMT and AV 
valve development. Dash lines represent signalling pathways shown by others. 
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3.5 DISCUSSION 
The present study was carried out to examine the role of NOS3 in AV valve 
formation. We demonstrated for the first time that deficiency in NOS3 leads congenital 
AV valve defects. Additionally, lack of NOS3 also impairs endocardial EndMT. 
Furthermore, we showed that cardiomyocyte-specific NOS3 overexpression mice 
completely rescued these defects in NOS3-/- mice. In order to assess the functional 
significance of these defects, echocardiography was carried out on P0 live animals. Our 
data showed severe regurgitation of both mitral and tricuspid valves in the NOS3-/- mice. 
This phenotype was accompanied by reduced ejection fraction and fractional shortening 
and increased atrial size. Moreover, cardiomyocyte-specific NOS3 overexpression 
completely rescued these phenotypes. Our study suggests that NOS3 promotes 
endocardial EndMT and embryonic development of AV valves (Figure 3.10C).  
The main function of AV valves is to prevent blood form flowing backwards from 
the ventricles to the atria during systole. Clinically, AV valve regurgitation can present in 
various forms depending on etiology and severity.29 In the case of acute AV valve 
regurgitation, heart failure and cardiogenic shock may occur leading to death as a result 
of backflow from the ventricles and volume overload.30, 31 Severe AV valve regurgitation, 
decreased heart dysfunction and increased in atrial size were observed in the NOS3-/- 
mice. These phenotypes highly resemble congenital AV valve insufficiency, a clinical 
condition with infants born with shortened or a complete lack of AV valves.32, 33 
However, it is possible that that mitral valve prolapse may also play a role in AV valve 
regurgitation seen in the NOS3-/- mice. NOS3-/- mice have coronary artery malformation 
which could lead to cardiac ischemia and papillary muscle dysfunction.20 This could 
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cause AV valve regurgitation. Although we cannot eliminate the possibility of mitral 
valve prolapse, we saw AV valve regurgitation accompanied by a phenotypic change of 
the AV valve structure. Therefore, our data support the notion that AV valve 
regurgitation is likely a result of AV valve insufficiency. Mitral valve insufficiency is 
often associated with other cardiac defects such as atrial septal defects (ASD), ventricular 
septal defects (VSD), aortic valve insufficiency and tricuspid valve insufficiency.34 
Tricuspid valve insufficiency, also known as tricuspid valve regurgitation, is also 
associated with congenital cardiac defects such as VSD and mitral valve regurgitation.32 
These accompanying cardiac defects are very similar to phenotypes seen in the NOS3-/- 
mice providing an excellent animal model to study AV insufficiency.18, 19 Clinically, AV 
valve insufficiency is a serious congenital heart disease with very limited options other 
than invasive open-chest surgery. The molecular mechanisms underlying this disease are 
still largely unknown. The present study on the role of NOS3 in AV valve formation 
provides a possible mechanistic explanation to AV valve insufficiency.  
Snail1, a zinc finger transcriptional repressor, is critical to induction of EndMT 
during embryonic development.28 Snail1 knockout mice have defects in mesoderm 
formation and die around E7.5.35 In addition, deletion of Snai1 specifically in the epiblast 
results in death by E9.5 due to multiple vascular defects and increased apoptosis.36 To 
investigate the role of NOS3 in early AV valve formation, in vivo Snail1 expression and 
ex vivo endocardial EndMT were assessed. Our results showed the number of Snail1 
positive mesenchymal cells and total number of endocardial cushion mesenchymal cells 
were significantly decreased in NOS3-/- compared with NOS3+/+ hearts at E10.5 and 
E12.5 (Figure 3.5). In addition, the total number of mesenchymal cells from E10.5 
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endocardial cushion cultures was significantly decreased in NOS3-/- explants (Figure 3.7A, 
B). These data show a reduction of endocardial EndMT in the NOS3-/- mice leading to 
malformation of mitral and tricuspid valves.  
TGFβ is expressed at high levels in AV mesenchyme during cushion formation 
and the critical to EndMT and AV valve development.37 Blockade of TGFβ2 by 
neutralizing antibody inhibits EndMT in mouse heart explants and TGFβ2 knockout mice 
show valvular defects.27, 38 BMP2 is also important for AV cushion EndMT. Nkx2.5 
mediated deletion of BMP2 reduced AV cushion formation and cellularity.39 A classic 
pathway by which NO mediates its biological function is through cGMP-dependent 
protein kinase G (PKG) signaling.40 In this regard, NO has been shown to upregulate 
TGFβ1 and BMP2 via PKG dependent pathway.41-43 In order to study the molecular 
mechanism by which NOS3 promotes endocardial EndMT and AV valve development, 
ex vivo E12.5 heart cultures were carried out to investigate the role of NO/cGMP 
signaling in the expression of TGFβ1, BMP2 and Snail1. We showed that inhibition of 
guanylate cyclase decreased TGFβ1, BMP2 and Snail1 expression in the WT hearts while 
treatment with 8-Bromo-cGMP increased TGFβ, BMP2 and Snail1 mRNA levels in the 
NOS3-/- hearts. These findings indicate that NOS3 acts as an upstream regulator of 
TGFβ1, BMP2 and Snail1 through a cGMP-dependent pathway. Notably, TGFβ1 and 
BMP are able to induce Snail1expression.15, 16 To this end, we showed that recombinant 
TGFβ treatment significantly increased Snail1 expression in both WT and NOS3-/- hearts. 
Taken together, our data suggest that cGMP production from NOS3 upregulates TGFβ 
and BMP2, and promotes Snail1 expression and EndMT, leading to normal AV valve 
development (Figure 3.10C).  
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In summary, endocardial EndMT, an important process required for 
valvulogenesis is impaired in NOS3-/- mice at E10.5 and E12.5, leading to malformation, 
insufficiency and regurgitation of AV valves at P0. We anticipate that these new insights 
into the mechanisms of AV valve development may lead to therapeutic strategies in the 
prevention and possibly treatment of AV valve insufficiency.  
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4.1 CHAPTER SUMMARY 
Aims: Spontaneous aortic valve thrombosis is an extremely rare event but its underlying 
mechanisms are still largely unknown. NO produced from NOS3 maintains endothelial 
cell integrity and inhibits platelet aggregation.  We aimed to study the role of NOS3 in 
maintaining normal function and morphology of the aortic valve in adult life and aging. 
We hypothesized that deficiency in NOS3 leads to spontaneous aortic valve thrombosis, 
calcification and dysfunction in aging mice. 
Methods and Results: At 12 months old, 72% (13/18) of NOS3-/- mice showed severe 
spontaneous aortic valve thrombosis compared with WT mice (0/12). When platelets 
were incubated with explanted aortic valves, platelet adhesion and aggregation to the 
NOS3-/- valves were significantly higher compared with the WT controls.  Additionally, 
significant regurgitation of the aortic valve during systole was observed using 
echocardiography in the NOS3
-/-
 but not in WT mice. Furthermore, NOS3 deficiency 
resulted in significant aortic valve stenosis, calcification and fibrosis. In ex-vivo aortic 
valve interstitial cell cultures, inhibition of NOS by L-NAME increased calcification in 
WT valves. In contrast, NO donor DETA-NO significantly inhibited calcification in 
NOS3-/- valves. 
Conclusion: Deficiency of NOS3 results in spontaneous aortic valve thrombosis, 
calcification and stenosis. Our study suggests that NOS3 is pivotal in maintaining the 
normal structure and function of the aortic valve in adulthood and aging.  
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4.2 INTRODUCTION 
Valvular heart disease (VHD) affects over 2.5% of the general population. This 
number dramatically increases to more than 13.3% of individuals over the age of 75.1, 2 
Over the next 25 years, world population statistics project that there will be a doubling of 
population in individuals between the age of 75 to 84.1 By this projection, individuals 
over the age of 75 affected by VHD will double in the next 25 years. VHD can present in 
many forms, one of which is the formation of a thrombus on the aortic valve.3, 4 The 
spontaneous formation of a thrombus on the aortic valve is extremely rare in humans with 
only less than a dozen of case reports in the literature.3-12 Although most of the cases 
were patients with tricuspid aortic valves, one case showed spontaneous aortic valve 
thrombosis was a result of calcific bicuspid aortic valve.5 However, aortic valve 
thrombosis is extremely dangerous, as it could lead to embolization, and subsequent 
cerebrovascular events such as stroke, myocardial infarction and death.3, 5-7, 11 
Thrombosis is formed via adhesion and aggregation of platelets at the site of tissue injury 
followed by fibrin clot formation. Many factors have been identified to be important 
inhibitors of platelet activation and aggregation, such as apyrase, prostaglandin I2 and 
nitric oxide (NO).13, 14 In addition, thrombosis formation can also be inhibited via 
inhibitors of coagulation cascade such as thrombomodulin, tissue factor pathway 
inhibitor (TFPI) and anti-thrombin III.15, 16 To our knowledge, spontaneous aortic valve 
thrombosis has never been studied in an animal model.  
Endothelial nitric oxide synthase (NOS3) belong to a family of enzymes known as 
nitric oxide synthases (NOS). NOS catalyze the reaction of L-arginine and NADPH 
producing NO. NO is a fast acting gaseous signaling molecule that is involved in many 
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physiological processes including apoptosis, angiogenesis, cell proliferation and 
differentiation.17-19 20 NOS3 is important in maintaining normal cardiovascular function 
including vasodilation, inhibition of inflammation and vascular smooth muscle 
proliferation, stimulation of angiogenesis and recruitment of endothelial progenitor 
cells.21 In pathophysiology, NOS3 polymorphism is associated with increased risk for 
cardiovascular disease, increased incidence of congenital heart disease, 
hypercholesterolemia, hypertension, diabetes and atherosclerosis.21 
Spontaneous thrombosis of aortic valve can be seen in patients with hyper-
coagulative state such as polycythemia or systemic lupus erythematosus with anti-
cardiolipin antibodies.22, 23 In addition, excessive valvular damage such as in the case of 
calcific aortic valve stenosis (CAVS) may induce thrombosis.5, 11 CAVS is the most 
common valvular disease.1 CAVS is characterized by progressive narrowing of the aortic 
valve resulting in aortic stenosis, calcification and thickening of the aortic valves and 
aortic valve regurgitation.24 Although calcified aortic valve has been associated with 
normal aging and valve degeneration, recent studies suggest that CAVS can be attributed 
to a genetic origin. Mutations in Notch1, an important factor that is involved in many 
developmental processes, has been shown to cause aortic valve disease similar to 
CAVS.25 Notch1 functions by repressing the activities of Runx2, a central transcriptional 
regulator in osteoblast cell fate.25 Importantly, NOS3 has been shown to act upstream of 
Notch1 in aortic valve interstitial cells cultured in vitro by altering Notch1 intracellular 
domain nuclear localization. 26 These findings suggest NOS3 may play a crucial role in 
aortic valve disease. The aim of our current study was to investigate the role of NOS3 in 
normal maintenance of aortic valve function and its role in aortic valve thrombosis and 
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calcification. We hypothesized that deficiency in NOS3 leads to spontaneous aortic valve 
thrombosis and calcification in the adult mice. 
4.3 METHODS 
4.3.1 Animals 
Breeding pairs of NOS3-/- (stock No. 002684) and wild-type C57BL/6 (WT) mice 
were purchased from Jackson Laboratory (Bar Harbor, Maine). A breeding program was 
carried out to produce neonates. Genotyping of NOS3-/- and NOS3+/+ mice was performed 
by a polymerase chain reaction (PCR) method using genomic DNA prepared from tail 
biopsies. All procedures involving mouse husbandry and manipulation were in 
accordance with the guidelines of the Canadian Council of Animal Care and approved by 
the Animal Use Subcommittee at the University of Western Ontario, Canada. 
4.3.2 General Tissue Processing 
WT and NOS3-/- mice were used for analysis. Hearts were isolated and fixed in 4% 
paraformaldehyde, dehydrated, and embedded in paraffin. Five micro-meter transverse 
serial sections were mounted onto albumin/glycerin coated glass slides.   
4.3.3 Immunohistochemistry and Immunofluorescence 
After deparaffination and rehydration, the slides were incubated for 3 minutes 
with 1% Sirius red solution for fibrosis, Mason’s Trichrome staining kit for collagen and 
muscle. Counterstaining was performed with 0.1% hematoxylin (Merck, Germany). 
Immunofluorescence was done using established protocols were used with minor 
modifications.27-29 Briefly, after deparaffination and rehydration of the slides, microwave 
antigen retrieval was applied by heating them for 10 min at 98°C in a citric acid buffer 
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(10 mM in aquadest, pH 6.0). The slides were incubated overnight with either 1:100 anti-
Runx2 (Santa Cruz, USA), 1:100 anti-E-selectin (Biotech, USA). Next, the goat anti-
rabbit secondary antibody conjugated with GFP (1:1000, Vector Laboratories, USA) was 
added for 60 min in PBS. Finally, 0.1% DAPI solution was used to stain nuclei.  
4.3.4 Heart Function Measurements 
Left ventricular (LV) and right ventricular ejection fraction and fractional 
shortening were measured using the Vevo 2100 ultrasound imaging system (Visual 
Sonics, Canada). Briefly, 2-dimensional images of the heart were obtained in short-axis 
view using a dynamically focused 40 MHz probe. The M-mode cursor was positioned 
perpendicular to the LV anterior and posterior walls. The LV internal end-diastolic 
dimension (LVIDd) and LV internal systolic dimension (LVIDs) were measured from M-
mode recordings. LV ejection fraction was calculated as: EF (%) = [(LVIDd)3 - 
(LVIDs)3]/(LVIDd)3×100. Fractional shortening was calculated as: FS (%) = (LVIDd-
LVIDs)/LVIDd×100. The M-mode measurements of the left ventricular ejection fraction 
and fractional shortening were averaged from 3 cycles. Aortic valve regurgitation and 
flow pattern were measured in both color flow Doppler recordings and pulsed-wave 
Doppler echocardiograms. 
4.3.5 Platelet Adhesion and Aggregation on Aortic Valves 
Aortic valves were dissected from WT and NOS3-/- 12 months old mice and 
cultured in M199 medium (Sigma-Aldrich, USA). Separately, the platelets were isolated 
from the same animals and treated with a Calcein dye (Life Technologies, Canada) for 15 
minutes under room temperature.  The aortic valves were then treated with WT or NOS3-
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/- platelets for 1 hour at 37ºC.  After the incubation period, the aortic valves were imaged 
under fluorescence microscope (Observer D1, Zeiss, Germany). 
4.3.6 Aortic Valve Interstitial Cell Cultures 
WT and NOS3-/- aortic valves were explanted from 9-12 week old adult mice and 
cultured in M199 medium (Sigma-Aldrich, USA). WT and NOS3-/- hearts were planted 
on a 35 mm petri dish coated with 1 mg/ml collagen type I gel for 6 days for attachment 
and to allow valve mesenchymal cells, which are valve interstitial cells (VICs) to migrate. 
After attachment, the aortic valves were treated with 300 µl of osteo-differentiation 
media along with L-NAME in WT aortic valves and DEAT-NO in NOS3-/- aortic valves. 
After 18 days of culture, cells were stained with 0.5% Alizarin red for calcification and 
imaged under phase contrast (Observer D1, Zeiss, Germany). The number of calcified 
mesenchymal cells was counted.  
4.3.7 Real Time RT-PCR 
Total RNA was isolated from aortic valves of 12 months adult WT and NOS3-/- 
mice with RNA isolation kit (Qiagen, Canada). cDNA was synthesized using M-MLV 
(Invitrogen, Canada) reverse transcriptase and random primers (Invitrogen, Canada). 
Real-time PCR was conducted using SYBR Green PCR Master Mix as per 
manufacturer's instructions (Eurogentec, USA). Samples were amplified for 35 cycles 
using Eppendorf Real-Time PCR machine. The expression levels of Notch1, Runx2, Sp7 
and β catenin in relation to 28S rRNA as a loading control were obtained. 
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4.3.8 Statistical Analysis 
Data are presented as mean ± SEM. Unpaired Student’s t test was used for 2 
group comparisons. One way ANOVA followed by Newman-Keuls test was performed 
for multi-group comparisons. P<0.05 was considered statistically significant. 
4.4 Results 
4.4.1 Severe spontaneous aortic valve thrombosis in NOS3-/- mice 
Severe spontaneous aortic valve thrombosis was observed in NOS3-/- mice at 12 
months old. Representative 3-D reconstructions of normal aortic valve of a WT mouse 
and a thrombus on the aortic valve of a NOS3-/- mouse are shown in Fig. 4.1A. The 
thrombus was positioned on the aortic side of the valve. Next, Masson’s trichrome 
staining was used to assess WT and NOS3-/- aortic valves. WT mice showed normal cross 
sectional aortic section with 3 distinct valve leaflets while 27% of NOS3-/- mice showed 
only 2 valve leaflets with an enlarged aortic valve thrombosis (Fig. 4.1B). Hematoxylin 
and eosin staining showed the formation of the thrombus originated from the aortic valve 
(Fig. 4.1C). The thrombus had an intense eosin staining due to fibrin deposition (Fig. 
4.1C). Quantitative analysis show 13/18 (72%) of NOS3-/- mice at 12 months of age had 
spontaneous aortic valve thrombosis, in which 100% (5/5) bicuspid aortic valve and 62% 
(8/13) tricuspid aortic valve NOS3-/- animals showed spontaneous aortic valve thrombosis. 
None of the WT showed any aortic valve thrombosis (P<0.0001 Fig. 4.1D). Because of 
hemodynamic changes, bicuspid aortic valve is associated with aortic valve calcification 
and thrombosis in humans. To study the specific role of NOS3 on spontaneous 
thrombosis and calcification, further analyses were done using mice with tricuspid aortic 
valves.  
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 In order to study the role of NOS3 in platelet adhesion and aggregation on the 
aortic valve, the aortic valves were explanted from WT and NOS3-/- 12 months old mice 
and incubated with platelets. After 1 hour of incubation with the valves, the amount of 
platelets on these valves was imaged and quantified. Our data show that WT and NOS3-/- 
platelets were adhered significantly more to the NOS3-/- compared to the WT aortic 
valves (Fig. 4.2A-B). Furthermore, NOS3-/- platelets were more adhesive to the NOS3-/- 
valves compared to WT valves. In addition, platelets formed clumps on the NOS3-/- aortic 
valves, indicating platelet aggregation (Fig. 4.2A).    
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Figure 4.1 Severe spontaneous aortic valve thrombosis in NOS3-/- mice at 12 months old. 
(A) 3-D reconstruction of aortic valves of WT and NOS3-/- mice. While WT mice have 
three aortic valve leaflets, NOS3-/- mice show a bicuspid aortic valve with a spontaneous 
aortic valve thrombosis (Marked in red). (B) Masson’s trichrome staining of WT and 
NOS3-/- aortic valves. NOS3-/- mice show only 2 valve leaflets with an enlarged aortic 
valve thrombosis. (C) Hematoxylin and eosin staining of a large thrombus on the aortic 
valve from a NOS3-/- mouse. This is the same animal used in (B) to show that the origin 
of the thrombus is from the aortic valves. (D) 72% of NOS3-/- mice but none of the WT 
mice at 12 months old had spontaneous aortic valve thrombosis. *P<0.0001 vs. WT  
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Figure 4.2 Platelet adhesion and aggregation on aortic valves. (A) WT and NOS3-/- 
tricuspid aortic valves were dissected from 12 months old mice and marked with calcein 
dye. These valves were then treated with WT or NOS3-/- platelets to assess platelet 
aggregation. (B) Quantification of platelet aggregation on WT and NOS3-/- aortic valves 
using fluorescence intensity. Data are mean  SEM from 4 mice per group. *P<0.05 vs. 
corresponding WT aortic valve (AV) groups, †P<0.05 vs. NOS3-/- AV+WT platelets (Pl). 
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4.4.2 Deficiency in NOS3 results in aortic valve regurgitation 
C57BL/6 WT and NOS3-/- mice cardiac and aortic functions were measured at 3, 
5, 9 and 12 months of age. Representative images showed normal systole blood flow in 
WT and NOS3-/- mice at 12 months (Fig. 4.3A). While systole blood flow was normal, 
diastolic blood flow showed severe aortic valve regurgitations in the NOS3-/- mice. This 
was evident on both the color and pulsed wave Doppler recordings (Fig 4.3A-B). Further 
quantifications showed that both regurgitation velocity and duration measured by pulsed 
wave Doppler recordings were significantly increased (Fig 4.3C, D). Starting at 3 months, 
29% of NOS3-/- mice showed mild to severe aortic valve regurgitation. This trend 
continued at 5, 9 and 12 months with 33%, 33% and 37% of NOS3-/- mice showed aortic 
valve regurgitation, respectively (Fig. 4.3E).  
Cardiac functions measured by left ventricular ejection fraction and fractional 
shortening were normal at 3, 5 and 9 months in WT and NOS-/- mice. However, left 
ventricular ejection fraction and fractional shortening were significantly decreased at 12 
months in NOS3-/- mice compare with age-matched WT controls (Fig. 4.4 A-C). In 
addition, left ventricular anterior wall thickness during diastole and systole were 
measured. Our data showed that there were no significant differences in the left 
ventricular wall thickness at any time point of the study. To further assess the NOS3-/- 
hearts, LV diameter were measure. Our data showed that there is no significant difference 
between WT (2.16±0.035) and NOS3-/- (2.304±0.077) LV diameter in 12 months old mice.  
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Figure 4.3 Severe aortic valve regurgitation in NOS3-/- mice. Regurgitation from aortic 
valves was determined by color (A) and pulsed-wave (B) Doppler echocardiography. 
Both WT and NOS3-/- mice show normal systolic outflow.  However, NOS3-/- mice show 
significant aortic valve regurgitation during diastole (A and B, red arrows). C-D. 
Quantification of aortic valve regurgitation. Significant aortic regurgitation was observed 
in NOS3-/- but not in WT mice. Data are mean  SEM from 6-7 mice per group. *P<0.01 
vs. WT. E. The percentage of animals that showed aortic valve regurgitation at 12 
months old.  
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Figure 4.4 Assessment of cardiac function using echocardiography. (A) Representative 
M-mode imaging showing decreased heart function in the NOS3-/- mice compared with 
WT controls at 12 months. (B-C) Left ventricular fractional shortening and ejection 
fraction at 3, 5, 9, and 12 months in NOS3-/- and WT mice. (D-E) Left ventricular wall 
thickness during systole and diastole in WT and NOS3-/- mice from 3 to 12 months.  Data 
are mean  SEM from 5 mice per group. *P<0.05 vs. WT. 
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4.4.3 Deficiency in NOS3 results in aortic valve fibrosis and thickening of the 
aortic wall 
To analyze collagen content, picro Sirius red staining was performed. NOS3-/- 
aortic valve showed much stronger Sirius red staining than the WT at 12 months (Fig 
4.5A, upper panel). Furthermore, the aortic wall in the NOS3-/- mice was thickened 
compared with age-matched WT controls (Fig. 4.5A, lower panel). Quantitative analysis 
showed that Sirius red staining intensity and aortic wall thickness were significantly 
increased in the NOS3-/- mice compared with age-matched WT controls (Fig. 4.5B, C). 
The total vascular smooth muscle cell numbers in the aortic wall were increased in NOS3-
/- mice. However, cell density per mm2 was not significantly different between NOS3-/- 
and WT controls (Fig. 4.5D). Moreover, the structure of the cells in the WT aortic wall 
was organized and aligned, while in the NOS3-/-, the cells within the aortic wall was 
disorganized and misaligned (Fig. 4.5A). Taken together, these results showed a 
vulnerable and disorganized aortic wall structure in the NOS3-/- mice that is associated 
hypertrophy of the aortic wall cells. 
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Figure 4.5 Aortic valve fibrosis and aortic wall thickening in 12 months old NOS3-/- 
mice. (A) Representative Sirius red and hematoxylin staining showing aortic fibrosis and 
wall thickening, respectively. (B) Quantification of fibrosis staining intensity.  (C) 
Quantification of aortic wall thickness. (D) Quantification of cell density in the aortic 
wall. Data are mean  SEM from 6-7 mice per group. *P<0.01 vs. WT. 
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4.4.4 Deficiency in NOS3 results in endothelial cell activation/damage 
Endothelial cell activation/injury may cause valvular damage and possibly aortic 
valve thrombosis.5, 6 To assess whether endothelial cell activation is seen in the NOS3-/- 
mice, sections were stained for the presence of E-selectin, which is an excellent marker 
for endothelial cell activation.30, 31 Our data showed E-selectin expression significantly 
increased in the NOS3-/- mice compared with WT mice (Fig. 4.6A). Further quantification 
showed significantly increased number of activated endothelial cells in the NOS3-/- mice 
compared with WT mice (Fig. 4.6B). To correlate this data with mRNA expression, E-
selectin mRNA expression was determined in the WT and NOS3-/- mice. Similar to 
protein staining, mRNA expression of E-selectin was significantly increased in the NOS3-
/- mice compared with WT mice (Fig. 4.6C). Vascular cell adhesion molecule 1 (V-CAM) 
and intercellular adhesion molecule 1 (I-CAM) are well known markers for endothelial 
cell activation.31 Our data showed mRNA levels of both V-CAM and I-CAM were 
significantly increased in the NOS3-/- mice compared with WT mice (Fig. 4.6D, E). 
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Figure 4.6 Endothelial cell activation of the aortic valve in NOS3-/- mice. (A) 
Representative histology images stained with E-selectin show endothelial cell activation 
in the NOS3-/- mice. (B) Quantification of E-selectin+ endothelial cells in WT and NOS3-/- 
mice. (C-E) Quantification of mRNA expression of well-known markers for endothelial 
cell activation. Data are mean  SEM from 4-5 mice per group. *P<0.05 vs. WT. 
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4.4.5 Deficiency in NOS3 results in severe aortic valve calcification 
To assess aortic valve calcification, aortic valves from WT and NOS3-/- mice were 
stained for the presence of Runx2, a marker of calcification (Fig. 4.7A). Our data showed 
that Runx2 expression was significantly increased in the NOS3-/- mice compared to age-
matched WT controls (Fig. 4.7C). In addition, B-mode echocardiography images showed 
brightened aortic valves, indicative of aortic valve calcification (Fig. 4.7A, red arrows). 
Quantitative analysis of the brightness density of the aortic valves showed that there was 
a significant increase in the NOS3-/- mice compared with age-matched WT controls (Fig. 
4.7B).  
Notch1 has been shown to be important in maintaining normal aortic valve function by 
repressing the transcription of Runx2.25, 32 To examine if NOS3 regulates Notch1 and 
Runx2 expression, mRNA was isolated from 12 months old WT and NOS3-/- aortic 
valves. Our data showed that the Notch1 mRNA levels were significantly decreased in 
the NOS3-/- mice compared with WT controls (Fig. 4.7D). Furthermore, the expression of 
Runx2 was significantly increased in NOS3-/- mice compared with WT controls (Fig. 
4.7E). To further confirm aortic valve calcification, we measured the expression of other 
well-known markers of calcification including Alkaline phosphatase 1, Sp7 and β-catenin,  
which were all significantly increased in the NOS3-/- mice compared with WT controls 
(Fig. 4.7F, H-I). Sox9 is a negative regulator of Runx2. Our data showed that Sox9 
mRNA levels were significantly decreased in the NOS3-/- mice compared with WT 
controls (Fig. 4.7G). 
 To further study a protective effect of NOS3 against aortic valve calcification, ex-
vivo cultures of aortic valve interstitial cells (VICs) were employed. The adult aortic 
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valve was harvested and plated on collagen to allow VICs to migrate out. These cells 
were then treated with an osteo-differentiation media in the presence of a nitric oxide 
synthase inhibitor L-NAME or a NO donor DETA-NO for 18 days. The cultured VICs 
were stained with Alizarin red to assess calcification. Our data showed that NOS3-/- VICs 
exhibited significantly more calcification compared with WT cells (P<0.05, Fig. 4.8A-B). 
Furthermore, when WT VICs were treated with osteo-differentiation media together with 
L-NAME, calcification was significantly increased compared with controls. Finally, 
when NOS3-/- aortic valve cells were treated with osteo-differentiation media in the 
presence of DETA-NO, calcification was significantly decreased compared with controls 
(P<0.05, Fig. 4.8A-B). Together, these data showed a key role of NO in inhibiting VIC 
calcification.  
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Figure 4.7 Severe aortic calcification in NOS3-/- mice. (A) Representative B-mode and 
histology images stained with Runx2. (B) Calcification can be analyzed from the 
brightness of the aortic valves in the B-mode echocardiography image (red arrows). (C) 
Quantification of number of Runx2 positive cells in the aortic valve. (D-I) Quantification 
of Notch, Runx2, AP1, Sp7, β-Catenin and Sox9 mRNA expression in WT and NOS3-/- 
mice at 12 months old. Data are mean  SEM from 4-7 mice per group. *P<0.01 vs. WT 
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Figure 4.8 Effects of NO on calcification of cultured aortic valve interstitial cells (VICs). 
(A) Representative images showing cultured VICs stained with Alizarin red for 
calcification. WT VICs were treated the osteo-differentiation media and a nitric oxide 
synthase inhibitor, L-NAME. NOS3-/- VICs were treated with osteo-differentiation media 
and a nitric oxide donor, DETA-NO. (B) Quantification of Alizarin red positive cells. N= 
3-4 cultures per group. *P<0.05 vs. WT Control. †P<0.05 vs.NOS3-/- Control.  
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4.5 DISCUSSION 
In the present study, we demonstrated for the first time that deficiency in NOS3 
leads to spontaneous aortic valve thrombosis, regurgitation, and calcification and fibrosis. 
Furthermore, we showed that the normal maintenance of aortic valves is dependent on 
NOS3 produced NO, which inhibits VIC calcification. Additionally, we showed that 
NOS3 regulates Notch1 and Runx2 signalling pathway to maintain normal aortic valve 
function.  Our study suggests that NOS3 plays a key role in the normal maintenance of 
aortic valves in adulthood and aging.  
Aortic valve thrombosis is extremely rare in the clinic. However, patients that 
have this disease are often fatal due to thrombus breakage and subsequent embolism 
resulting in stroke and myocardial infarction.5-7, 11 Increases in platelet aggregation are 
associated with thrombus formation in patients with protein S deficiency or anti-
phospholipid syndrome.4, 7, 12 In the present study, the NOS3-/- aortic valves were more 
prone to platelet adhesion and aggregation.  Furthermore, NOS3-/- platelets had a 
significantly higher aggregation compared to WT platelets on NOS3-/- aortic valves, 
suggesting that NOS3 from both platelets and aortic valves contributes to inhibition of 
platelet aggregation on aortic valves. Thus, lack of NOS3 from both platelets and aortic 
valves may lead to aortic valve thrombosis in the aging NOS3-/- mice. Additional, 
endothelial activation/injury can be a result of normal wear and tear during aging or 
underlying disease condition such as calcification of the aortic valve.5, 6 Normally, NO 
production from NOS3 protects endothelial cells from oxidative injury. 21 Additionally, 
NOS3 promotes the recruitment of circulating endothelial progenitor cells, which 
regenerate and repair the injured endothelium.33 However, in the NOS3-/- mice, these 
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protective mechanisms are lost, resulting in thrombus formation. To our knowledge, this 
is the first study that links NOS3 function to the spontaneous formation of an aortic valve 
thrombus. 
The function of aortic valves is to prevent backflow of blood from the outflow 
tracts into the ventricles during diastole. The normal aortic valves are made up of 3 
distinct cusps which evenly distribute the mechanical stress to the valve annulus and 
aorta. When the even distribution of mechanical stress is disrupted such as in the case of 
bicuspid aortic valves, part of the valve may have a higher stress and valvular endothelial 
cells may get activated, leading to platelet aggregation and eventually the formation of 
spontaneous aortic valve thrombosis. Previous studies have demonstrated that about 30% 
of NOS3-/- animals show bicuspid aortic valve phenotype.34-36 In the present study, NOS3-
/- mice with bicuspid aortic valve all developed spontaneous aortic valve thrombosis 
(100%). However, in tricuspid aortic valve NOS3-/- animals, only 61.5% developed 
spontaneous aortic valve thrombosis. It appears that mice with bicuspid aortic valves are 
possibly more susceptible to the formation of spontaneous aortic valve thrombus. 
However, due to a small sample size, there was no statistical difference in the incidence 
of aortic valve thrombosis between these 2 groups of NOS3-/- mice. Experiments are 
ongoing to increase the sample size of NOS3-/- mice. In CAVS, the valve cusps become 
progressively fibrotic and calcified.37 This results in stiffened valves, reduced valve 
movements and progressive valve narrowing resulting in aortic stenosis. If left untreated, 
CAVS leads to left ventricular hypertrophy and eventually congestive heart failure and 
death.38, 39 Aortic valve calcification plays a key role in the disease progression of 
CAVS.40 Studies have shown that Notch1/Runx2 signalling limits aortic valve 
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calcification.25  Notch1 is a transcription factor that is involved in many developmental 
processes including liver, skeleton, heart, eye, face, kidney and vasculature.41 More 
importantly, Notch1 mutations are associated with abnormal development of the aortic 
valve including bicuspid aortic valve and aortic valve stenosis.25, 42 A reduction of Notch 
signalling decreases epithelial to mesenchymal transition (EMT), which is necessary for 
proper formation of aortic valves.43 In the adult aortic valve, Notch1 signalling activates 
Hairy-related transcription, which physically interacts with Runx2, a master regulator of 
osteoblast differentiation, and represses its transcriptional activity.44, 45 Activation of 
Runx2 would result in osteoblast differentiation and calcification in the aortic valves.  In 
our study, NO inhibits osteogenic differentiation of VICs, consistent with previous 
findings.46, 47   We further demonstrated that Notch1 expression is significantly decreased 
in the NOS3-/- aortic valves compared with age-matched WT controls, suggesting that 
NOS3 regulates Notch1 expression.26  Decreased Notch1 activity would increase Runx2 
expression, leading to osteoblast differentiation and aortic valve calcification.  
In summary, the present study demonstrates a pivotal role of NOS3 in limiting 
aortic valve from thrombosis and calcification, and maintaining normal aortic valve 
function. These beneficial effects NOS3 are likely mediated through the regulation of 
Notch1 and Runx2. We believe this is an excellent animal model to study spontaneous 
aortic valve thrombosis and the disease progression of CAVS. We anticipate that these 
new insights into the role of NOS3 in maintaining normal aortic valve function may lead 
to therapeutic strategies in the prevention and possibly treatment of spontaneous aortic 
valve thrombosis and CAVS. 
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5 CHAPTER 5  
DISCUSSION 
5.1 SUMMARY OF MAJOR FINDINGS AND DISCUSSION 
The overall objective of this thesis was to investigate the regulatory role of NOS3 
in the heart during embryonic development and adulthood. More specifically, I studied 
the role of NOS3 in the embryonic development of coronary artery, the formation of 
atrioventricular valves and the maintenance of adult aortic valves (Figure 5.1). To 
achieve these goals, NOS3 genetic knockout animals were used and a novel cardiac 
specific NOS3 overexpressing mouse was generated. Experimental approaches included 
in vitro cell cultures, ex vivo heart cultures and in vivo animal studies as well as the use of 
pharmacological inhibitors and adenoviral constructs.  
In Chapter 2, I investigated the role of NOS3 in coronary artery development 
(Figure 5.1). I demonstrated that neonatal NOS3-/- mice show severe abnormalities in 
coronary arteries. Furthermore, as early as E15.5, coronary artery diameters, density and 
volume were significantly decreased in the NOS3-/- compared with WT embryos. In order 
to understand the molecular mechanism governing morphogenesis of the coronary 
arteries, expression of transcription and growth factors critical to coronary development 
was analyzed in E12.5 hearts. Interestingly, the expression of Gata4, VEGFa, bFGF and 
EPO was down-regulated in the NOS3-/- compared with WT embryonic hearts. 
Additionally, Wilm’s tumour-1 (Wt1), a transcription factor critical for EMT and 
coronary artery formation, was also down-regulated and the number of epicardial derived 
cells (EPDC) was decreased in the NOS3-/- hearts. These data suggest that NOS3 is 
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critical to embryonic coronary artery development. It has been shown that NOS3 
promotes proliferation in many cell types.1-3 For example, NOS3 promotes neonatal 
cardiomyocyte proliferation by inhibiting TIMP-3 expression.1 NOS3 also promotes 
migration of mesenchymal stem cells towards the heart.4 Therefore it is possible that not 
only cell migration, but also cell proliferation of EPDCs is affected in the NOS3-/- mice. 
Thus, a combination of decreased transcription and growth factors and decreased ability 
of EPDC proliferation and migration into the myocardium may impair coronary artery 
development in the NOS3-/- mice.  
NOS3-/- mice show impaired coronary artery development partially due to 
decreased EMT of the epicardium. EMT has also been shown to be crucial to 
atrioventricular valve development in the embryonic heart. Thus, in Chapter 3, I 
investigated the role of NOS3 in atrioventricular valve formation (Figure 5.1). I 
demonstrated that for the first time that deficiency in NOS3 leads to impairment of 
endocardial EMT and congenital AV valve defects. Furthermore, I showed that 
cardiomyocyte-specific NOS3 overexpression mice completely rescued these defects in 
NOS3-/- mice. In order to assess the functional significance of these defects, 
echocardiography was carried out on P0 live animals. Our data showed severe 
regurgitation of both mitral and tricuspid valves in the NOS3-/- mice. This phenotype was 
accompanied by reduced ejection fraction and fractional shortening and increased atrial 
size. Moreover, cardiomyocyte-specific NOS3 overexpression completely rescued these 
phenotypes. To investigate the role of NOS3 in early AV valve formation, in vivo Snail1 
expression and ex vivo endocardial EMT were assessed. Our results showed the 
expression of Snail1 was significantly decreased in NOS3-/- compared with WT hearts at 
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E12.5. In addition, explant culture of endocardial cushions from E10.5 mice showed that 
the total number of mesenchymal cells was significantly decreased in NOS3-/- explants. 
These data show a reduction of endocardial EMT in the NOS3-/- mice leading to 
malformation of mitral and tricuspid valves. Our study suggests that NOS3 promotes 
endocardial EMT and embryonic development of AV valves. To further understand the 
underlying signaling mechanism, I showed that inhibition of guanylate cyclase decreased 
TGFβ1, BMP2 and Snail1 expression in the WT hearts while treatment with 8-Bromo-
cGMP increased TGFβ, BMP2 and Snail1 mRNA levels in the NOS3-/- hearts. Both 
TGFβ1 and BMP have the ability to stimulate Snail1expression.5, 6 To this end, we 
showed that recombinant TGFβ treatment significantly increased Snail1 expression in 
WT and NOS3-/- hearts compared with respective controls. Taken together, our data 
suggest that cGMP production from NOS3 upregulates TGFβ and BMP2, and promotes 
Snail1 expression and endocardial EMT, leading to normal AV valve development.  
In Chapter 4, I investigated the role of NOS3 in the normal maintenance of aortic valve 
function (Figure 5.1). I demonstrated for the first time that deficiency in NOS3 leads to 
severe aortic valve thrombosis, regurgitation, aortic stenosis and aortic valve calcification 
and thickening. Deficiency in NOS3 resulted in severe spontaneous aortic valve 
thrombosis at 12 months old. Histological analysis showed the formation of a thrombus 
originated from the aortic valve. Quantitative data showed that 72% of NOS3-/- mice at 12 
months old had spontaneous aortic valve thrombosis. None of the WT showed any aortic 
valve thrombosis. In order to test platelet aggregation of WT and NOS3-/- mice, an ex vivo 
aortic valve culture explant was carried out. Our data showed that platelet aggregation 
was significantly increased in NOS3-/- aortic valves. In addition, the NOS3-/- aortic valves 
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showed clumping of platelets similar to that occurs in thrombus formation. Additionally, 
severe aortic valve regurgitation was observed in the NOS3-/- mice. This phenotype 
started at 3 months with 28.5% of NOS3-/- mice showing mild to severe aortic valve 
regurgitation and continued at 5, 9 and 12 months with 33.3%, 33.3% and 36.8% of 
NOS3-/- mice having aortic valve regurgitation, respectively. Furthermore, NOS3-/- mice 
had aortic stenosis starting at 3 months old. As expected, this phenotype persisted at 5, 9 
and 12 months. Moreover, the aortic wall in the NOS3-/- mice was thickened compared 
with age-matched WT controls.  To analyze calcification, aortic valves were harvested 
from 12 months old WT and NOS3-/- mice and stained with Runx2, a marker of 
calcification. My data showed that Runx2 staining was significantly increased in the 
NOS3-/- mice compared with age-matched WT controls. Furthermore, when WT aortic 
valve cells treated the osteo-differentiation media in the presence of L-NAME, a nitric 
oxide synthase inhibitor, calcification was significantly increased compared with controls. 
When NOS3-/- aortic valve cells were treated with osteo-differentiation media in the 
presence of DETA-NO, a nitric oxide donor, calcification was significantly decreased 
compared with controls. Finally I showed that the mRNA expression of Notch1 was 
significantly decreased in the NOS3-/- mice and Runx2 mRNA levels were significantly 
increased in NOS3-/- mice compared with WT controls. These results were expected since 
Notch1 represses the activity of Runx2 in normal aortic valves.7, 8  Taken together, my 
study suggests that NOS3 plays a crucial role in the normal maintenance of aortic valves 
during adulthood and aging.  
In summary, I have demonstrated a crucial role of NOS3 in normal heart 
development and in the maintenance of postnatal aortic valve function. More specifically, 
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I showed that NOS3 is required for coronary artery development and deficiency in NOS3 
leads to hypoplastic coronary arteries. Next, I showed that NOS3 promotes endocardial 
EMT and the formation of AV valves during embryonic heart development. Finally, I 
showed deficiency in NOS3 results in thrombosis formation and calcification of aortic 
valves, suggesting an important role of NOS3 in maintaining normal function and 
morphology of aortic valves. A summary of these findings and previous work using 
NOS3-/- mice is shown in Figure 5.2. My studies may provide important information for 
developing novel therapeutic strategies for the treatment of congenital heart disease and 
adult valvular disease.  
5.2 STUDY LIMITATIONS  
5.2.1 Mouse Models of Human Disease Conditions   
Genetically modified mice used as models of human disease conditions are 
necessary in the evaluation of potential therapeutics for both ethical and practical reasons. 
The use of mouse models allows for the collection of tissue samples, and the control of 
experimental conditions that are otherwise not possible in humans.  Over 99% of all 
mouse genes can be traced to a human homologue thus providing a genetic  
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Figure 5.1 Proposed signaling pathway of NOS3 on coronary artery development, 
atrioventricular valve formation and adult aortic valve maintenance. NOS3 promotes the 
expression of Wt1, Gata4, TGFβ, BMP2 and Notch1 via cGMP. Wt1 and Gata4 promote 
coronary artery development via EPDC migration and growth factor signalling, 
respectively. TGFβ and BMP2 regulate AV valve formation via activation of Snail1 and 
EMT in the endocardial cushion. Finally, Notch1 expression inhibits Runx2 and prevents 
adult aortic valve calcification. Lack of NOS3 induces endothelial activation and 
thrombosis of aortic valves in aging.  
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Figure 5.2 Summary of the biological effects of NOS3 on the heart during embryonic 
development and postnatal life. 
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system that correlates well with the human genome.9 Finally, the mouse genome is 
relatively easy to manipulate and this provides an enormous amount of possibilities for 
genetic modification to study various human related diseases.10  
This thesis utilized a variety of in vitro and in vivo experimental models to 
simulate human heart disease. In vivo, Chapters 2 and 3 used a neonatal mouse model to 
study the role of NOS3 in coronary artery development and atrioventricular valve 
formation. Chapter 4 used an adult mouse model to study the role of NOS3 in the 
normal maintenance of the aortic valves. In humans, NOS3 polymorphisms with reduced 
enzyme activity have been shown to be correlated with congenital heart disease and 
coronary artery disease.11 In my studies, deficiency in NOS3 expression results in 
congenital heart defects including malformations of coronary arteries and impaired 
atrioventricular valve development (Chapters 2 and 3) and adult aortic valve thrombosis, 
stenosis and calcification  (Chapters 4). Previous studies from our lab also showed 
deficiency in NOS3 results in congenital heart defects such as atrial and ventricular septal 
defects.12 Whole-body knockout animals and the genetic mutation or polymorphisms in 
human disease may not be directly comparable. In humans polymorphisms of NOS3 have 
been associated with congenital heart disease and coronary artery disease.11, 13-15 These 
polymorphisms represent a reduction in the enzyme activity, not a complete deletion of 
NOS3. Therefore we would expect the severity of the phenotypes to be much greater in 
the animal models. Indeed, in our NOS3-/- mice, up to 80% of offspring dies within the 
first 5 days of life compared with the polymorphisms seen in humans which has not been 
associated with postnatal mortality.12 Next, even though in this case the phenotypes in 
NOS3-/- animals are similar to humans, it is not certain that these phenotypes are a 
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primary defect caused by the deficiency of NOS3 in the heart. For example, it is possible 
that whole-body knockout of NOS3 leads to changes in other organ systems and through 
these changes causing a secondary effect on the heart leading to congenital heart disease. 
To address this issue, we have generated a cardiac-specific NOS3 transgenic mouse under 
the control of -myosin heavy chain promoter. Expression of human NOS3 was detected 
only during embryonic development and specifically in the heart of NOS3Tg mice. The 
NOS3Tg mice were then crossed with NOS3-/- to create the NOS3Tg;NOS3-/- mouse, an 
animal that lacks NOS3 in all organs except the heart during embryogenesis. cGMP, a 
critical downstream signaling molecule of NOS3, was significantly decreased in the 
NOS3-/- compared with WT hearts at postnatal day 0 (P0). This animal model allowed use 
to study the effect of NOS3 specifically in the heart and our data support an important 
role of myocardial NOS3 in embryonic heart development.  
For in vitro cell cultures, we isolated ventricular myocytes and epicardium 
derived cells (Chapter 2) and cushion cells (Chapter 3) from the embryonic hearts. We 
also isolated aortic valve tissues from the hearts of adult mice (Chapter 4).  The use of in 
vitro cultures presents a problem as these cells may, under certain circumstances, respond 
differently than in vivo conditions. For example, the fact that in vivo ventricular myocytes 
are under the constant nourishment from the blood supply as well as its physical and 
biochemical interaction with surrounding environment simply cannot be duplicated in 
any in vitro cultures. In my studies, these cultures were used to overcome technical 
barriers in vivo. When studying the developing heart or a very specific tissue in the adult 
heart (aortic valves), in vivo manipulations of the tissue of interest is simply not 
technically possible. Therefore, we have to employ methods of in vitro culturing to 
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delineate the role of NOS3 in these tissues. Notably, our in vitro delineation of 
mechanisms has provided new insights on the pathogenesis of phenotypes in the NOS3-/- 
mice.  
In summary, this thesis utilized transgenic and knockout mouse models to study 
the role of NOS3 in embryonic heart development and in maintaining normal aortic 
function during postnatal life. However, murine research also has inherent limitations in 
that the mouse heart is different from the human heart. For example the mouse heart beats 
approximately 7 times faster and 250 times smaller than the adult human heart. The most 
important differences in cardiac structure of human and mouse are confined to the atria. 
In the mouse, unlike the human counterpart, there is no extensive formation of a 
secondary atrial septum.16 Thus, the relevance of any NOS3-mediated effects described in 
this thesis ultimately needs to be confirmed in humans. 
5.2.2 Use of Pharmacological Inhibitors to Delineate Signaling Pathways 
In Chapter 2 and 3 of this thesis, I used nitric oxide donors DETA-NONOate, as 
well as nitric oxide inhibitors such as L-NAME. These agents are easy to use, and have 
previously been shown to be effective in increasing or decreasing the availability of NO 
to cells. DETA-NONOate belongs to the family of diazeniumdiolates that release low 
levels of NO spontaneously at physiological conditions.17 The half-life of DETA-
NONOate under physiological pH is approximately 20 hours and therefore, it is a slow 
acting prolonged NO donor that mimics NOS3 when given at low μM concentrations.18 
L-NAME is an analogue for L-arginine. It competes with L-arginine for the substrate 
binding site on NOS. However, unlike L-arginine, L-NAME cannot be converted to L-
citrulline and therefore NO production is inhibited.19 Although L-NAME is considered a 
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non-selective NOS inhibitor, it appears to have a higher selectivity to NOS3 than 
iNOS.20, 21 Therefore, the choices of the nitric oxide donor and inhibitor are based on the 
understanding of their functions, and studies using these agents to ensure proper dosing 
and selectivity. However, as is the case with all pharmacological compounds, I cannot 
rule out the non-specific effects of the pharmacological agents. For example, L-NAME (2 
µM) can also inhibit the production of prostaglandins and interleukin-1 beta.20, 21 In my 
studies, I used pharmacological agents as a secondary verification of genetic 
manipulations such as genetically altered mice. Thus I am confident that the results I 
obtained are indeed due to alterations of NO levels rather than non-specific effects of 
these agents. 
5.3 SUGGESTIONS FOR FUTURE RESEARCH 
The novelty of this thesis is the demonstration that NOS3 is crucial in the 
developing heart and maintenance of adult aortic valve function. However, there are 
many valuable aspects of the role of NOS3 during development still warrant further 
investigation.   
In Chapter 2, I observed that NOS3 deficiency leads to coronary artery 
malformations. Coronary artery development involves many complex highly regulated 
steps. The epicardium first undergoes epithelial-to-mesenchymal transition (EMT) and 
gives rise to epicardium-derived cells (EPDCs), which migrates into the myocardium to 
form smooth muscle cells and fibroblasts that are essential for the development of 
coronary arteries.22-24 Recent clonal analysis confirmed earlier studies in avian embryos 
that the endothelium of the coronary vascular system derives from endothelial sprouts of 
sinus venosus with a minor contribution from the endocardium.25-27 Thus, endothelial 
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cells from sinus venosus and endocardium, and vascular smooth muscle cells and 
fibroblasts derived from EPDCs contribute to the formation of coronary arteries. 
Coronary artery development is further divided into major coronary artery development, 
coronary artery capillary vessel development and coronary vessels connection to the aorta. 
In this thesis and previous studies from our lab showed deficiency in NOS3 leads to 
major coronary artery malformations and decreased coronary capillary vessels 
development. However, we did not look at the role of NOS3 in the connection of 
coronary vessels to the aorta. In humans and mice, many coronary artery anomalies can 
occur.28-30 For example, both left main and right main coronary artery are connected to 
the same sinus of Valsalva of the aorta.29, 30 Whether a disruption of NOS3 mediates the 
abnormal connection of coronary arteries to the aorta is an interesting area to pursue for 
future studies. 
In addition to studying the role of NOS3 in coronary artery development, one 
potential project could look at other vascular development in the body. There are major 
similarities in vessel development in the developing embryo. For example, it has been 
shown lungs of NOS3-deficient mice also exhibit a paucity of distal arteriolar branches 
and capillary hypoperfusion, which resemble alveolar capillary dysplasia in humans.31 
The finding is consistent with the role of NOS3 in capillary development and 
angiogenesis.32, 33  
Additionally, during development of the cardiac conduction system, Purkinje 
fibers receive paracrine cues from developing coronary vessels.34, 35  Inhibition of 
coronary artery development decreases Purkinje fiber differentiation suggesting that 
coronary arteries are necessary and sufficient for the induction of Purkinje fibers.34 Thus, 
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it is possible that coronary artery defects in NOS3-/- mice may impede the development of 
the cardiac conduction system. 34, 35 Whether lack of NOS3 impairs development of 
cardiac conduction system remains to be investigated.  
In Chapter 3, I demonstrated that deficiency in NOS3 leads to congenital 
atrioventricular valve insufficiency and severe atrioventricular valve regurgitation. They 
only represent 2 of the 4 valves involved in the regulation of blood flow in the developing 
heart. The other 2 valves are aortic valve, which controls the blood flow between the left 
ventricle and outflow aorta and pulmonary valve, which controls the blood flow between 
the right ventricle and outflow pulmonary artery. Previous study showed the deficiency in 
NOS3 results in bicuspid aortic valve formation, which is a congenital malformation with 
only 2 instead of 3 valve leaflets.  However, that study did not assess the development of 
the pulmonary valves. Bicuspid pulmonary valves are extremely rare and are often 
associated with other congenital cardiac defects. Isolated bicuspid pulmonary valve is 
exceedingly rare condition. Because of the extremely rare occurrence of bicuspid 
pulmonary valve, this condition is often under studied. Therefore, it is worthwhile to look 
at the role NOS3 in the development of pulmonary valves and to assess whether 
deficiency of NOS3 results in the formation of bicuspid pulmonary valves.   
In Chapter 4, I showed that deficiency of NOS3 leads to calcified aortic valve 
stenosis. I demonstrated phenotypes of aortic valve regurgitation, stenosis, thickening and 
calcification of the valves. In the clinic, later stages of untreated calcified aortic valve 
stenosis are associated with left ventricular hypertrophy and eventually heart failure. 
Unfortunately we did not see these phenotypes in the 12 months NOS3-/- animals. It 
would be interesting to study these animals at 18 or 24 months to see if they develop left 
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ventricular hypertrophy and heart failure. In addition, it would be interesting to see the 
condition of others valves in these aged mice. More specifically, the function of the 
pulmonary, mitral and tricuspid valves can be assessed to see if these phenotypes are 
limited to the aortic valves or it may apply to all valves within the aging heart.  
5.4 CLINICAL APPLICATION 
          Over the past decade, mutations and polymorphisms of the NOS3 gene have been 
identified in association with coronary artery disease.13-15 In addition, a recent study 
showed the common G894T polymorphism, which has reduced NOS3 function, is also a 
risk factor for congenital heart disease.11 This finding is consistent with the role of NOS3 
in heart development in mice.12, 36, 37 Taken together, these findings help to establish a 
critical role of NOS3 in early heart development in both humans and mice. The present 
thesis showed for the first time a critical role of NOS3 in the developing heart and in the 
maintenance of adult aortic valve functions. Along with our current understanding of 
NOS3 mutations and polymorphisms as a risk factor, reduced NOS3 function not only 
puts individuals at higher risk of developing coronary artery disease and congenital heart 
disease,4, 11, 13-15 but may also affect embryonic coronary artery development, 
atrioventricular valve development and aortic valve dysfunction and calcification in the 
next generation through heritable mutations and polymorphisms in the NOS3 gene. 
Furthermore, we propose individuals with heritable mutations and polymorphisms in the 
NOS3 gene may be at risk for HCAD, atrioventricular valve insufficiency and calcified 
aortic valve stenosis. We anticipate that these new insights into the mechanisms of 
coronary artery development, atrioventricular valve development and maintenance of 
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adult aortic valve function may lead to therapeutic strategies in the prevention and 
treatment of congenital heart disease and adult valvular disease. 
5.5 CONCLUSIONS 
This thesis provides the first evidence that NOS3 is crucial in the development of 
the coronary artery, the formation of atrioventricular valves and the adult maintenance of 
aortic valve function. While further investigation is required to determine the therapeutic 
potential of NOS3 in the treatment of HCAD, atrioventricular valve insufficiency and 
calcified aortic valve stenosis, it is clear that NOS3 is required in the development heart 
as well as normal valvular function in the adult. Furthermore, this work has provided 
valuable insight into the mechanisms by which NOS3 is involved in coronary artery 
development (Chapter 2), formation of the atrioventricular valves (Chapter 3) and 
maintenance of adult aortic valve function (Chapter 4). Overall my doctoral research has 
broadened our understanding of NOS3 in the developing heart and regulation of normal 
adult valvular function, and may contribute to the development of therapeutics for the 
treatment of HACD, atrioventricular valve insufficiency and calcified aortic valve 
stenosis. 
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